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Summary  XII 
V Summary 
Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease characterized 
by accumulation of activated myofibroblasts and excessive extracellular matrix 
deposition, in part mediated through enhanced TGF-β signaling. TGF-β1 is a potent 
inducer of epithelial-to-mesenchymal transition (EMT), the reversible phenotypic 
switching of epithelial to fibroblast-like cells. Recently, EMT has been demonstrated in 
alveolar epithelial cells (AECs) and has been proposed as a causative factor in lung 
fibrosis, but its precise mediators and mechanisms in IPF remains to be resolved. During 
developmental and disease settings, the phenotypic conversion of the epithelium is under 
tight transcriptional control, however, the transcription factors eliciting EMT in IPF have 
yet to be identified. Putative roles for SNAI transcription factors as regulators of EMT 
during development and a wide variety of diseases including cancer and organ fibrosis 
have been documented. 
This study is based on the hypothesis that in AECs, TGF-β1-induced SNAI 
transcription factors facilitate the acquisition of new morphology and motility, based on 
their ability to influence EMT marker gene expression. Thus, the objective of this study 
was to analyze the molecular mediators of TGF-β1-induced EMT in vitro, in human 
A549 and primary mouse AT2 cells, and to assess their contribution to the development 
of fibrosis in experimental and idiopathic pulmonary fibrosis in vivo.   
Immunofluorescent costaining of Tjp1 and α-SMA (an epithelial and 
mesenchymal marker, respectively) demonstrated TGF-β1-induced EMT in AECs. 
Furthermore, in vitro, TGF-β1 treatment increased the expression and nuclear 
accumulation of the zinc finger transcription factors SNAI1 (Snail) and SNAI2 (Slug), as 
assessed by RT-PCR and immunofluorescence. Ectopic expression of SNAI1 and SNAI2 
proteins was sufficient to induce EMT in A549 cells, even in the absence of TGF-β1 
stimulation. In contrast, the siRNA-mediated depletion of SNAI1 and SNAI2 attenuated 
TGF-β1-induced AEC migration and EMT in A549 cells. The detection of EMT in vitro, 
with an increase in SNAI transcription factors was substantiated in vivo in the bleomycin 
model of pulmonary fibrosis early in disease. In vivo, SNAI expression was elevated in 
Summary  XIII 
primary AECs isolated from fibrotic lungs, seven days after bleomycin challenge. An 
indication of occurrence of EMT with an increase in SNAI transcription factors was also 
corroborated in IPF patient lungs compared to control lungs. Furthermore, the occurrence 
of EMT, as well as the involvement of transcriptional control of SNAI factors was 
clarified in a unilateral ureteral obstruction (UUO) mouse model of renal fibrosis. 
This study shows that (1) TGF-β1-induced EMT in alveolar epithelial cells is 
accompanied by elevated expression of SNAI transcription factors, (2) EMT in AECs is 
essentially controlled by SNAI transcription factors, as ectopic expression of SNAI1 and 
SNAI2 triggers EMT, whereas depletion of these factors abrogates TGF-β1-induced 
EMT, (3) increased expression of these zinc finger transcription factors are detected in an 
experimental model of lung fibrosis, with indication of the occurrence of EMT, (4) 
SNAI1 and SNAI2 upregulation have important implications for the development of IPF, 
(5) the detection of SNAI transcription factors early in EMT in a UUO model of renal 
fibrosis and the inhibition of EMT by leukocyte blocker treatment further emphasizes the 
significance of SNAI transcription factors in EMT as a causal factor in disease. Thus, 
reversal and/or inhibition of EMT may present a valid therapeutic option in lung fibrosis. 
 
 
Zusammenfassung  XIV 
VI Zusammenfassung 
Die idiopathische pulmonale Fibrose (IPF) ist eine fatale interstitielle 
Lungenerkrankung, die durch Ansammlung von aktivierten Myofibroblasten und 
verstärkter extrazellulärer Matrixbildung gekennzeichnet ist. An diesem Vorgang ist der 
TGF-β Signalweg beteiligt. Zudem induziert TGF-β1 die epitheliale-mesenchymale 
Transition (EMT), die reversible phänotypische Umwandlung von epithelialen zu 
fibroblasten-ähnlichen Zellen. Kürzlich konnte EMT in Alveolarepithelzellen in der 
Lungenfibrose gezeigt werden. Während des Entwicklungsprozesses und bei vielen 
Krankheiten, wie Krebs und Fibrose unterliegt die phänotypische Umwandlung des 
Epithels strengen Transkriptionsvorgängen. Die einzelnen Transkriptionsfaktoren, die 
EMT in IPF hervorrufen, sind noch zu identifizieren. Die vermeintliche Rolle von SNAI 
Transkriptionsfaktoren als EMT Regulatoren in anderen Erkrankungen wurde schon 
dokumentiert. 
Die vorliegende Studie basiert auf der Hypothese, dass TGF-β-induzierte SNAI 
Transkriptionsfaktoren in alveolaren Epithelzellen EMT-Markerexpression beeinflussen 
können und somit die Morphologie und Motilität der Zellen verändern können. Das Ziel 
dieser Arbeit war es, die molekularen Mechanismen von TGF-β1-induzierter EMT in 
vitro, in humanen A549 Zellen und primären murinen Alveolarepithelzellen zu 
untersuchen. Dabei galt es ihre Beteiligung bei der Entwicklung in experimenteller und 
idiopathischer pulmonaler Fibrose in vivo zu beurteilen. 
Die TGF-β1-induzierte EMT in Alveolarepithelzellen wurde anhand epithelialer 
Proteinen (Tjp1) und mesenchymaler Proteinen (α-SMA) durch Immunfluoreszenz 
nachgewiesen. Des weiteren wurde in vitro, nach Behandlung mit TGF-β1, eine erhöhte 
Expression und nukleäre Ansammlung der Zinkfingerproteine SNAI1  und SNAI2 mittels 
quantitative RT-PCR und Immunfluoreszenz ermittelt. Die ektopische Expression von 
SNAI1 und 2 war bereits ausreichend, um EMT in A549 Zellen zu induzieren; auch ohne 
TGF-β1 Stimulation. Im Gegensatz dazu, führte eine siRNA vermittelte Verringerung 
von SNAI1 und 2 zur Abschwächung einer TGF-β1 induzierten Migration von 
Alveolarepithelzellen und EMT in A549 Zellen. Der Nachweis von EMT in vitro mit 
Zusammenfassung  XV 
Anstieg an SNAI Transkriptionsfaktoren konnte in vivo im Bleomycinmodell der 
pulmonalen Fibrose belegt werden. Sieben Tage nach Bleomycin Exposition zeigten 
primäre Alveolarepithelzellen aus fibrotischen Lungen eine Erhöhung der SNAI 
Expression. Auch in IPF Lungen bestätigte sich dieses Ergebnis im Vergleich zu 
gesunden Lungen. Außerdem konnte EMT, sowie die Beteiligung von 
transkriptionskontrollierten SNAI Faktoren im Mausmodell der renalen Fibrose, einer 
unilateralen urethralen Obstruktion (UUO), nachgewiesen werden. 
Zusammenfassend konnte gezeigt werden, dass die TGF-β1-induzierte EMT in 
Alveolarepithelzellen mit einer erhöhten Expression von SNAI Transkriptionsfaktoren 
einher geht. Die Überexpression von SNAI1 und 2 zeigte, dass diese 
Transkriptionsfaktoren den EMT-Prozeß im wesentlichen triggern, während eine 
Verringerung dieser Faktoren die TGF-β1-induzierte EMT aufhebt. Die Erhöhung dieser 
Zinkfingerproteine, mit dem Hinweis auf EMT, konnte zudem in einem experimentellen 
Modell der Lungenfibrose nachgewiesen werden. Diese Beobachtung bestätigte sich 
ebenfalls in humanen IPF-Proben. Der Nachweis von SNAI Transkriptionsfaktoren in 
EMT im renalen Fibrosemodell, der UUO, und die Hemmung von EMT durch 
Behandlung mit Leukozytenblockern, heben die Signifikanz dieser Faktoren als Ursache 
im Krankheitsmechanismus hervor. Eine Aufhebung und/oder Hemmung von EMT 
könnte somit eine Therapiemöglichkeit in der Behandlung der Lungenfibrose darstellen.  
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1 Introduction 
1.1 Idiopathic pulmonary fibrosis 
1.1.1 Characteristics of idiopathic pulmonary fibrosis 
Idiopathic Pulmonary Fibrosis (IPF; also termed Cystic Fibrosing Alveolitis, 
CFA) is a chronically progressive, often fatal lung disease resulting in irreversible 
distortion of the lung architecture. The etiology of this disease still remains unknown. IPF 
has been classified as one of the seven types of Idiopathic Interstitial Pneumonia (IIP) 
and unlike the other forms of IIPs, IPF cannot be resolved by currently available 
treatment (W.D. Travis and T.E. King, Jr, 2002).  
This disease has an insidious onset and occurs worldwide ( T.E. King, Jr , 2000). 
The prevalence of IPF is high in the male sex (male: female prevalence ration 1.4: 1.0) 
(N. Khalil, et al., 2004). The incidence of IPF is associated predominantly with increasing 
age and the majority of patients are over 60 years of age. Cigarette smoking, genetic 
factors, infectious agents, and environmental pollutants have been identified as some of 
the potential risk factors associated with this disease. The prognosis of IPF is poor with 
an overall median length of survival varying between 2.5 and 3.5 years after diagnosis 
(W.D. Travis and T.E. King, Jr, 2002). 
Criteria for diagnosis of IPF are based on a combined consensus provided by the 
American Thoracic Society, European Respiratory Society, and the American College of 
Chest Physicians which encompasses clinical, radiological, and pathological information. 
Clinically, IPF is characterized by exertional dyspnea, nonproductive cough, inspiratory 
crackles termed velcro crackles, and digital clubbing. Worsening of pulmonary function 
is frequently encountered on physical examination. Bronchoalveolar lavage (BAL) fluid 
cellular analysis shows increased neutrophils and eosinophils. Severe pulmonary 
hypertension and cor pulmonale may be encountered late in the course of the disease 
(W.D. Travis and T.E. King, Jr, 2002, T.J. Gross, et al., 2001). Chest radiographs and 
High Resolution Computed Tomography (HRCT) scan suggest decreased lung volume, 
bilateral reticular opacities prominent in the lung periphery and lower lobes, areas of 
ground-glass appearance, septal thickening, subpleural honeycomb cysts and or traction 
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 Figure 1.1 Histopathological changes observed in IPF. (A) Low 
magnification view of UIP, showing temporal heterogeneity, with 
dense collagen deposition on the left, and patchy areas containing 
normal alveolar septa present nearby (right and bottom center). A
characteristic zone of microscopic honeycomb change  
(arrowheads) and a fibroblast focus (arrow) is seen in an area of 
fibrosis and inflammation in the center of the field. Hematoxylin 
and eosin; original magnification is ×48. (B) Fibroblast focus in 
UIP (arrows) showing aggregate of spindle-shaped cells arranged in 
parallel beneath hyperplastic alveolar lining cells. Hematoxylin and 
eosin; original magnification is ×300 (A.L. Katzenstein, et al., 
1998). 
bronchiectasis (A.L. Katzenstein, et al., 1998). The appearance of histopathological 
patterns of Usual Interstitital Pneumonia (UIP) on surgical lung biopsy establishes the 
definitive pathological diagnosis of IPF and is associated with a poor prognosis (T.E. 
King, Jr., et al., 2001). 
1.1.2 Histopathological changes in idiopathic pulmonary fibrosis 
Pathological features that are routinely observed in IPF include alveolar epithelial 
cell damage, increased deposition of extracellular matrix (ECM) in the lung interstitium, 
enhanced fibroblast/myofibroblast proliferation and activation, and ultimately, distortion 
of normal lung architecture. The typical distribution of pathological changes is 
heterogeneous, with subpleural, basal, and predominantly peripheral distribution. The 
unique, typical histological features of IPF are termed UIP, which are increasingly used 
to distinguish IPF from other forms of IIP (W.D. Travis and T.E. King, Jr, 2002).  
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Low magnification power microscopy reveals temporal heterogeneity, a key 
feature of UIP (Figure 1.1). Temporal heterogeneity features areas of normal pulmonary 
parenchyma interspersed with interstitial inflammation, fibrosis, honeycombing changes, 
scattered fibroblast foci, and thickened alveolar septae lined by hyperplastic 
pneumocytes. Inflammation is usually mild to moderate, comprising primarily of 
lymphocytes and plasma cells, and occurs in areas of collagen deposition. Areas of 
honeycomb changes are composed of enlarged and distorted airspaces which are 
frequently lined by bronchiolar epithelium and filled with mucin (W.D. Travis and T.E. 
King, Jr, 2002).  
The hallmark lesions of IPF are fibroblast foci, which are sites featuring activated 
myofibroblasts, synthesizing and depositing a collagen-rich ECM, and are located just 
beneath hyperplastic type II pneumocytes. Fibroblast foci are considered to be the earliest 
lesions in UIP and their presence is an important prognostic factor and their number has 
been shown to correlate with survival in IPF (T.E. King, Jr., et al., 2001, E.S. White, et 
al., 2003). High power magnification shows dense acellular collagen bundles with 
smooth muscle metaplasia. Alveolar epithelial injury with hyperplastic type II 
pneumocytes is often seen at areas of active fibrosis (E.S. White, et al., 2003) (Figure 
1.1). 
1.1.3 Pathogenesis of idiopathic pulmonary fibrosis 
The precise mechanism that provokes IPF remains elusive. Much debate 
regarding the pathogenesis of IPF has recently been initiated, and the following theories 
have been postulated concerning current concepts in pathogenesis of IPF. 
1.1.3.1 The inflammation fibrosis theory 
Initially, the classic concept that chronic inflammation triggered by an 
unrecognized stimulus being the primary cause of fibrosis was widely accepted (T.J. 
Gross, et al., 2001). Some of the premises for this long-prevailing belief were that local 
inflammation was a prominent feature in fibrotic lungs of all the IIPs and the BAL of IPF 
patients contained increased numbers of inflammatory cells (S. Harari, et al., 2005, M. 
Kelly, et al., 2003, T.E. King, Jr., et al., 2001, V.J. Thannickal, et al., 2004) However, 
studies with transgenic animals revealed that inflammatory response could be dissociated 
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 Figure 1.2 Hypothetical scheme of the main pathogenic events 
in IPF. Unknown insults provoke multiple microscopic foci of 
epithelial damage and stimulation. Activated alveolar epithelial 
cells release factors inducing fibroblast migration and proliferation. 
In the microenvironment of the lesion, myofibroblasts induce 
epithelial cell apoptosis and basement membrane disruption, thus 
contributing to abnormal re-epithelialization and perpetuation of a 
vicious circle (M. Selman, et al., 2001). 
 
from fibrosis (P.J. Sime, et al., 1997). Furthermore, clinical trials in IPF patients did not 
reveal any beneficial response to anti-inflammatory therapy (F. Chua, et al., 2005, J. 
Gauldie, et al., 2002, M. Selman, et al., 2001). These contradictory findings and the lack 
of compelling evidence failed to substantiate the inflammatory fibrosis hypothesis. 
1.1.3.2 Abnormal wound healing theory 
An alternate hypothesis regarding the pathogenesis of IPF has recently emerged. 
The new hypothesis is based on the notion that IPF is a disorder of inappropriate alveolar 
regeneration in response to repetitive epithelial injuries, rather than an inflammatory- 
driven disorder (M. Selman, et al., 2001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As illustrated in Figure 1.2, repeated episodes of acute injury to discrete 
peripheral areas of the lung by unidentified insult results in alveolar epithelial cell injury. 
This delays re-epithelialization and leads to denuded, disrupted basement membrane (E.S. 
White, et al., 2003). These cells subsequently produce exudates, which in turn promote 
fibroblast activation, proliferation, and migration into the wound. Fibroblasts may also 
secrete mediators that promote alveolar epithelial cell apoptosis. Formation of fibroblast 
foci featuring exaggerated mesenchymal cell proliferation leading to excessive ECM 
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deposition, which in turn distorts the normal lung structure with compromised gas 
exchange function and ultimately results in IPF (M. Selman, et al., 2001, M. Selman, et 
al., 2002). 
The histological features of IPF suggest an inflammatory cause, but clinical 
findings and gene transfer studies in animal models support the concept of inflammation- 
independent fibrosis. However, some recent studies supports the role of acute and chronic 
inflammation in fibrosis and thus, a role for inflammation in IPF cannot be ruled out 
(G.W. Hunninghake, et al., 2003, F. Zuo, et al., 2002). The current view argues that the 
pathogenesis of IPF is complex and involves abnormalities in multiple pathways during 
both inflammation and wound healing (J. Gauldie, et al., 2002, R.M. Strieter, 2005). 
1.1.4 Key effector cells in idiopathic pulmonary fibrosis 
1.1.4.1 Alveolar epithelial cells in idiopathic pulmonary fibrosis 
In adults, the epithelial component of alveoli comprises type I and type II alveolar 
epithelial (AT1 and AT2) cells. The flattened AT1 pneumocytes cover more than 90% of 
the alveolar surface area of the peripheral lung, while the large, rounded AT2 
pneumocytes cover 7% of the alveolar surface. AT1 and AT2 cells represent 8% and 16% 
of the total alveolar cells, respectively. AT1 cells interface with pulmonary capillaries 
and provide an intact surface of minimal thickness readily permeable to gases. The AT2 
cells, which are often found in the corners of alveoli, are multifunctional cells that 
synthesize, store and secrete pulmonary surfactant, directionally transport sodium from 
apical to basolateral cell surfaces to minimize alveolar fluid, and participate in the 
immune response by producing molecules involved in innate host defence. AT2 cells are 
capable of undergoing mitosis and serve as progenitors of type I cells during homeostasis, 
as well as during lung injury. This differentiation is essential to re-establish a functional 
alveolar epithelium (M. Selman, et al., 2006). 
AECs in IPF are morphologically abnormal, exhibiting heterogeneous phenotypes 
(M. Kasper, et al., 1996, A.L. Katzenstein, et al., 2002, M. Selman, et al., 2003). 
Numerous hyperplastic and hypertrophic AT2 pneumocytes, with abundant cytoplasm, 
large hyperchromatic nuclei, and prominent nucleoli are present in the fibrotic thickened 
alveolar septa. Large and elongated epithelial cells and, flattened and attenuated epithelial 
cells, overlying the fibroblastic foci are also observed. 
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 Figure 1.3 Alveolar epithelial transdifferentiation pathways. 
AECs demonstrate pluripotency. Under normal conditions, AT2 
cells transdifferentiate into AT1 cells, and this process is reversible 
in vitro. Depending on the cellular environment and stimuli, AECs 
respond to injury by traveling down one of a number of pathways:
apoptosis or necrosis (1); proliferation, transdifferentiation, and re-
epithelialization (2); or EMT (3) to a myofibroblast phenotype, 
resulting in extracellular matrix (ECM) deposition, destruction of 
lung architecture, and fibrosis (B.C. Willis, et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The reasons and significance of these various phenotypic alternations in the AECs 
in IPF still remain unresolved. However, it is speculated that these phenotypic alterations 
in AECs may result from the initial injury and also that the differentiation of AT2 into 
AT1 pneumocytes is profoundly altered in IPF, which may be a key event culminating in 
fibrosis. Furthermore, these cells serve as the primary source of mediators such as     
TGF-β, Platelet-derived growth factor (PDGF), Tumor necrosis factor-α (TNF-α) that are 
capable of inducing fibroblast proliferation and activation, as well as, ECM accumulation 
in IPF (M. Selman, et al., 2006). As illustrated in Figure1.3, according to the new 
paradigm, owing to the high plasticity of AECs and in part depending on the degree and 
nature of injury, AECs may contribute to diverse cellular pathways, such as, restoration 
of normal architecture by re-epithelialization, apoptosis or fibrogenesis (B.C. Willis, et 
al., 2006). 
1.1.4.2 Fibroblasts in idiopathic pulmonary fibrosis 
Fibroblasts are dynamic cells that play crucial role in maintenance of matrix 
homoeostasis, and synthesis and degradation of a diverse group of extracellular 
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 Figure 1.4 Source of myofibroblasts in IPF. Three prominent 
sources of myofibroblast have been proposed. Myofibroblasts can 
arise by proliferation of resident fibroblasts, from circulating 
fibrocytes, or from transitioning of alveolar epithelial cells 
(modified from C.J. Scotton, et al., 2007). 
 
molecules. The maintenance of homoeostasis is essential for the preservation of normal 
tissue function, which is lost in IPF. During IPF, fibroblasts exhibit an activated 
myofibroblasts phenotype. Myofibroblast accumulation, activation, and impaired 
apoptosis are key features of pathobiology of IPF. Myofibroblasts possess features 
intermediate between fibroblasts and smooth muscle cells. They are contractile, 
expressing α-smooth muscle actin stress fibers and depositing excess ECM, resulting in 
structural remodeling that compromises lung function (E.S. White, et al., 2003). Despite 
the controversy surrounding IPF pathogenesis, it is well accepted that the interstitial 
fibroblast/myofibroblast represents the key effector cell responsible for the increased 
ECM deposition that is characteristic of IPF.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The number of α-smooth muscle actin-positive, activated myofibroblasts is 
significantly increased in multiple forms of pulmonary fibrosis including IPF (B. Hinz, et 
al., 2007), but their origin remains to be elucidated. Currently, three major theories 
attempt to explain the accumulation of activated myofibroblasts in the lungs of IPF 
patients, depicted in Figure 1.4. First, it has been demonstrated that resident pulmonary 
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 Figure 1.5 Morphological changes during EMT. During the 
process of EMT, well-differentiated epithelial cells revert to 
mesenchymal cells by loss of their highly polarized morphology, 
junctional complexes and undergo cytoskeletal rearrangment. They 
acquire a mesenchymal phenotype with invasive ability. The 
reverisble switching of mesenchymal cells to epithelial cells is 
termed mesenchyal-to-epithelial transition (MET) (modified from 
D.C. Radisky, et al., 2005). 
 
fibroblasts proliferate in response to fibrogenic cytokines and growth factors, thereby 
increasing the fibroblast pool via local fibroproliferation (S.H. Phan, 2002). Second, 
several recent studies have shown that bone marrow-derived circulating fibrocytes cells 
traffic to the lung during experimental lung fibrosis, and may serve as progenitors for 
interstitial fibroblasts (B.B. Moore, et al., 2006, R.J. Phillips, et al., 2004). Third, it was 
recently proposed that alveolar epithelial type II (AT2) cells are capable of undergoing 
epithelial-to-mesenchymal transition (EMT) (M. Selman, et al., 2006, B.C. Willis, et al., 
2005). 
1.2 Epithelial-to-mesenchymal transition 
1.2.1 Characteristics of epithelial and mesenchymal cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
Epithelial and mesenchymal cells represent distinct lineages, each with a unique 
gene expression profile that imparts attributes specific to each cell type. Epithelial cells 
are polarized, closely adjoined by membrane associated specialized junctions such as 
adherens junctions, tight junctions, gap junctions and desmosomes. These cells attach to 
an underlying basement membrane or basal lamina. Several studies have identified 
specific epithelial markers, such as, E-cadherin, a prototypic epithelial adhesion molecule 
in adherens junction (H. Peinado, et al., 2004); Tjp1 and occludin, integral components of 
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tight junctions. Epithelial cells are polarized and often secrete glandular products from 
the apical surface and some also secrete ECM from the basal surface (J. Zavadil, et al., 
2005).  
By contrast, mesenchymal cells do not have apical-basolateral polarity, 
specialized membrane structures or basal lamina. They contact neighboring mesenchymal 
cells only focally. Mesenchymal cells display actin cytoskeleton aggregated in stress 
fibers, which endows these cells with migratory ability. Vimentin, α-SMA, fibronectin, 
collagen precursors, talin, α-actin and β-filamin are some of the phenotypic markers 
characteristic of mesenchymal cells (J.P. Thiery, 2003). 
1.2.2 Key cellular events during EMT 
Garry Greenburg and Elisabeth Hay recognized EMT as a distinct process in 1982 
(G. Greenburg, et al., 1982). This multi-step event results in the phenotypic, reversible 
switching of epithelial to fibroblast-like or mesenchymal cells. The orchestrated series of 
events resulting in EMT include remodeling of epithelial cell-cell and cell-matrix 
adhesion contacts, reorganization of the actin cytoskeleton, and induction of 
mesenchymal gene expression. The cell morphology changes from a cuboidal to a 
fibroblastic shape. During EMT, epithelial cells lose apical basal polarity and acquire 
front-end back-end polarity. EMT endows the sedentary cell with the ability to become 
motile. They may start expressing gelatinase and the invasive activity allows them to pass 
through the underlying basement membrane. Epithelial marker expression gradually 
decreases while mesenchymal marker expression increases inversely, in cells adopting a 
mesenchymal phenotype. These changes in marker expression have been considered the 
hallmarks of EMT (P. Savagner, 2001). Numerous cellular changes are associated with 
EMT, but not all EMTs exhibit the whole range of changes (B. Boyer, et al., 2000). The 
precise spectrum of changes that occur during EMT is probably determined by the 
integration of extracellular signals the cell receives, although this is still unclear (J.P. 
Thiery, 2003). As depicted in Figure 1.6, EMT has emerged as a fundamental process 
during embryonic development. It has recently been recognized as a potential mechanism 
for cancer progression and fibrosis. EMT occurs during both physiological and 
pathological states (M.A. Huber, et al., 2005). 
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 Figure 1.6 EMT in development and disease. EMT is an 
evolutionary-conserved process occuring during gastrulation and 
neural crest development. In adults, EMT contributes to cancer by 
facilitating invasion and metastasis, and also promotes fibrosis of 
epithelial organs such as the kidney, liver and lungs (modified from 
D.C. Radisky, et al., 2005; R. Kalluri, et al., 2003). 
 
1.2.3 Role of EMT in embryos 
EMT is an evolutionary conserved process, initially discovered and described in 
embryonic development and morphogenesis in multicellular organisms. In vertebrates, it 
facilitates the formation of a three-layered embryo by gastrulation. EMT is also pivotal 
for organogenetic processes and contributes to the formation of the neural crest, heart, 
musculoskeletal system, craniofacial structures and peripheral nervous system (M.A. 
Huber, et al., 2005, J.P. Thiery, 2003). 
 
 
 
 
 
 
 
 
 
 
 
1.2.4 Role of EMT in adults 
EMT is a highly controlled, spatio-temporally regulated process that does not 
occur under usual circumstances in adults (B. Boyer, et al., 2000). However, EMT has 
been reported to play an integral role in wound healing. The reactivation and 
inappropriate induction of developmental EMT in adults leads to a variety of pathogenic 
conditions. EMT has gained wide recognition as a mechanism that facilitates cancer 
progression and metastasis, as well as, the development of chronic degenerative fibrotic 
disorders of the epithelial organs namely kidney, liver and lung. 
1.2.4.1 EMT in wound healing 
Following epithelial injury, EMT has been implicated in accelerating wound 
closure and healing process. Studies in keratinocytes have revealed the occurrence of 
EMT during skin wound healing (P. Savagner, et al., 2005). Contraction and re-
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epithelilalization are the main requisites of wound repair. The key cell types involved in 
this process are myofibroblasts and epithelial cells. Epithelial injury can be repaired 
through formation of granulation tissue, a provisional structure generated by ECM 
deposition, fibroblast proliferation, angiogenesis and immune cell influx. Myofibroblasts 
are the key cells involved in the creation of granulation tissue. An additional function of 
myofibroblasts is ECM contraction, through the formation of stress fibers containing     
α-SMA. Normally, completion of injury repair is followed by degradation of the 
provisional ECM and apoptosis of the myofibroblasts, however, sustained myofibroblast 
activation stimulates dysfunctional repair mechanisms, leading to the accumulation of 
fibrotic ECM that is rich in collagens which coalesces into fibrous bundles resistant to 
degradation (V.J. Thannickal, et al., 2004).  
1.2.4.2 EMT in cancer 
Numerous observations in tissue culture models of epithelial cells, transgenic 
mouse tumour models and human tumour biopsies support the idea that EMT has a 
central role in tumor progression (M.A. Huber, et al., 2005). During progression to 
metastatic competence, carcinoma cells acquire mesenchymal gene expression patterns 
and properties. EMT also enables cells to evade apoptosis, and it is widely-accepted as a 
mechanism underlying metastasis. The changes in adhesive properties and the activation 
of proteolysis and motility are specifically associated with tumor invasiveness, and also 
enable tumor cells to metastasize and establish secondary tumors at distant sites (J.P. 
Thiery, 2003). 
1.2.4.3 EMT in fibrosis 
In adults, EMT is speculated to occur during wound healing, involving resident 
epithelial cells, in response to injury as an additional source of fibroblasts. The molecular 
basis of EMT with respect to fibrosis is starting to emerge (R. Kalluri, et al., 2003), and 
much that is known about the mechanisms underlying EMT has been gleaned from 
studies on embryogenesis and carcinogenesis. In organ fibrosis, enhanced fibroblast 
proliferation and activation is considered unfavorable, as it leads to an increase in fibrotic 
scar formation. EMT has been extensively studied in renal fibrosis. Recently, EMT has 
also been implicated in the fibrosis of various other organs including the lung, liver, 
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anterior sub capsular cataracts in humans (A.M. Hales, et al., 1994, S. Saika, et al., 2004, 
B.C. Willis, et al., 2005, M. Zeisberg, et al., 2007) . 
The most convincing evidence for EMT as a source of myofibroblasts in vivo was 
derived from a study utilizing a model of gammaGT-LacZ transgenic mice, in which 
genetically-tagged proximal tubular epithelial cells gave rise to up to 36% of interstitial 
fibroblasts via EMT, following unilateral ureteral obstruction (UUO), a model of acute 
renal injury (M. Iwano, et al., 2002). Further evidence for the importance of EMT in the 
progression of chronic renal disease has been provided by the observation that MET, the 
reversal of EMT, results in resolution of fibrosis (M. Zeisberg, et al., 2005). These 
observations underscore the possible importance of EMT in the kidney fibrosis, and 
similar mechanisms may also apply to other epithelial organs like lung and liver, where 
tissue fibrosis eventually leads to impairment of organ function.  
1.2.4.4 EMT in idiopathic pulmonary fibrosis 
In the lung, AT2 cells are believed to serve as progenitors for repair of the 
alveolar epithelium following injury. They are capable of both self-renewal and of giving 
rise to AT1 cells (B.C. Willis, et al., 2007). Recently, in vitro studies have demonstrated 
that AT2 cells from both human (H. Kasai, et al., 2005) and murine (K.K. Kim, et al., 
2006, B.C. Willis, et al., 2005) origins can transition into fibroblasts upon stimulation 
with TGF-β1, a potent inducer of EMT. Another study showed that epithelial cells 
contributed to the increase in fibroblasts in vivo, wherein triple transgenic mouse with 
lung epithelial cells tagged for β–galactosidase, were treated with TGF-β1 (K.K. Kim, et 
al., 2006). The co-localization of EMT markers was demonstrated in AT2 cells in lung 
biopsies from IPF patients (K.K. Kim, et al., 2006, B.C. Willis, et al., 2005). This also 
demonstrated the high plasticity of AT2 cells. The lung epithelial plasticity is an area of 
active research. Collectively, these studies strongly suggest that alveolar epithelial cells 
may serve as a possible source of fibroblasts in lung fibrosis. The extent to which this 
process contributes to fibrosis following injury in the lung is also a subject of active 
investigation. 
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1.2.5 Inducers of EMT 
Several mechanisms are involved in initiating and executing EMT. EMT can be 
induced by a number of extacellular mediators individually or in combination. Several 
elicitors of EMT have been identified as ECM components, such as collagen as well as 
growth factors, including Epidermal growth factor (EGF), scatter factor or hepatocyte 
growth factor, Wnt ligands and members of the Fibroblast growth factor (FGF) and TGF-
β families (P. Savagner, 2001). In the majority of epithelial cell types and transgenic 
mouse tumour models, these mediators of EMT activate diverse signal transduction 
pathways, which have emerged as important for EMT. These pathways can be activated 
by specific signals, but are also controlled by crosstalk between each other. Induction of 
EMT appears to be highly tissue- and cell- type-specific, because factors that induce 
EMT under some circumstances can have quite different effects in others (J.P. Thiery, 
2003). 
1.2.5.1 TGF-β is a major inducer of EMT 
Transforming growth factor (TGF)-β represents a main inducer and regulator of 
EMT in multiple organ systems, during embryonic development, cancer progression, as 
well as organ fibrosis. TGF-β signaling is typically associated with the induction and 
maintenance of EMT. Knowledge of the precise molecular mechanisms mediating    
TGF-β- induced-EMT is beginning to emerge (M.A. Huber, et al., 2005). 
TGF-β was initially characterized after purification from human placenta in 1983 
(C.A. Frolik, et al., 1983). Subsequently, more than 60 members of TGF-β superfamily of 
growth factors have been identified. Members of the TGF-β family are pleotrophic, as 
they exert extremely diverse biological effects on a large variety of cell types. TGF-β and 
its family members control cell division, migration, adhesion, cell-fate determination and 
differentiation, and apoptosis. TGF-β signaling is essential for embryonic development 
and adult tissue homeostasis (B. Schmierer, et al., 2007). The TGF-β ligands consist of 
three highly homologous isoforms, TGF-β1, TGF-β2, and TGF-β3 (A.B. Roberts, 1998). 
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 Figure 1.7 Schematic diagram of the TGF-β signaling pathway 
from the cell membrane to the nucleus. The arrows indicate 
signal flow. At the cell surface, the ligand binds to the type I / type 
II receptor complex and induces phosphorylation of the GS segment 
(red) in the type I receptor. Consequently, R-Smads are 
phosphorylated, form a complex with Smad4 and this translocates 
into the nucleus to regulate transcription of target genes, assisted by 
either co-activators or co-repressors. R-Smads and Smad4 shuttle 
between the nucleus and the cytoplasm. Smurf1, Smurf2, Smad6, 
and Smad7 function as inhibitors of TGF-β signaling (R. Derynck, 
et al., 2003). 
1.2.5.2 Sensing and propagating TGF-β signals 
Members of the TGF-β superfamily initiate their cellular action through a family 
of transmembrane receptor-linked serine/threonine kinases. These receptors include a 
short cystine-rich extracellular domain, a single transmemebrane domain, and an 
intracellular serine/threonine kinase domain (J. Massague, 1996). Three functional 
classes of receptors can be distinguished: type I, type II, and type III. Seven type I 
receptors (ALKs 1–7), termed activin receptor- like kinases (ALKs) and five type II 
receptors (ActR-IIA, ActR-IIB, BMPRII, AMHR-II and TβR-II) have been identified in 
vertebrates (P. ten Dijke, et al., 2004). The type III (TβRIII) receptor recently was shown 
to enhance TGF-β signaling (J. Massague, et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the absence of ligand, TβRI and TβRII are present as homodimers in the 
plasma membrane (L. Gilboa, et al., 1998). As illustrated in Figure 1.7, upon binding to 
TGF-β, the TβRII receptor forms a heteromeric complex with the TβRI receptor, 
Introduction  15 
resulting in the phosphorylation of conserved Gly/Ser-rich (GS box) in type I receptor 
and thereby activating TβRI. TβRI in turn propagates signals to intracellular signaling 
mediators known as Smads (J.L. Wrana, et al., 2000). 
1.2.5.3 Smad proteins 
Signaling from activated TβRI to the nucleus occurs predominantly by 
phosphorylation of cytoplasmic protein mediators belonging to the Smad family. Smads 
can be divided into three classes based on their functional properties: the receptor-
regulated Smads (Smad 1, 2, 3, 5, and 8), the common Smad (Smad4), and the 
antagonistic Smads (Smad 6 and 7). They all consist of conserved amino and carboxyl 
terminal Mad homology (MH) domains that are separated by a linker region. The N-
terminal MH1 domain has DNA-binding activity, whereas the C-terminal MH2 domain 
has protein-binding and transactivation properties.  
In the absence of phosphorylation, Smads are transcriptionaly inert. The type I 
receptors for TGF-β, activin, nodal and myostatin (ALKs 4, 5 and 7) phosphorylate 
Smads 2 and 3, whereas the Bone morphogenetic protein (BMP) and Anti-Müllerian 
hormone (AMH) type I receptors (ALKs 1, 2, 3 and 6), phosphorylate Smads 1, 5 and 8. 
The phosphorylated Smad then forms a heteromeric complex with Smad4, which in turn 
translocate into the nucleus and regulate the transcription of target genes, both positively 
and negatively. Smads constantly undergo cycles of receptor-mediated phosphorylation 
and phospatase-mediated dephosphorylation, and thereby shuttle in and out of the 
nucleus. Smad 6 and 7 diverge structurally from other members of the Smad family and 
function as inhibitors of TGF-β signaling (J. Massague, et al., 2006, P. ten Dijke, et al., 
2004, F. Verrecchia, et al., 2007, O. Eickelberg, et al., 2007).  
In addition to the Smad pathway, non-Smad signal transduction downstream of 
TGF-β receptors has been proposed to occur in a cell-type-dependent manner. TGF-β has 
been shown to activate other mediators such as the mitogen-activated protein kinases 
(MAPKs).Extracellular signal regulated kinase (ERK), Jun N-terminal kinase (JNK), p38, 
Phosphoinositide 3-kinases (PI3K), PP2A phosphatases and Rho family members          
(J. Massague, et al., 2006). 
Introduction  16 
1.2.5.4 Role of TGF-β in idiopathic pulmonary fibrosis 
There are a number of cytokines and growth factors that are found in IPF tissue 
however, whether each or all play a pathogenic role in progressive fibrosis is unknown, 
but TGF-β1 in particular is thought to have a pivotal role in fibrogenesis. This 
multifunctional cytokine is a key regulator of ECM assembly and remodeling, and is an 
integral component of fibrotic tissue in IPF (T.J. Broekelmann, et al., 1991, R.K. Coker, 
et al., 2001, K. Ask, et al., 2008). Elevated TGF-β1 expression was detected in IPF lung 
tissue in contrast to that of normal adult lungs. No differences in TGF-β2 and TGF-β3 
isoform levels were noted (N. Khalil, et al., 1996). 
A more direct evaluation of the impact of TGF-β1 involves the transient 
overexpression of active TGF-β1 in lungs of rodents, using adenoviral vector-mediated 
gene transfer. Within a few days of introducing the vector, spontaneously active TGF-β1 
was expressed and there was evidence of tissue remodeling culminating in pulmonary 
fibrosis, without any pronounced inflammation. Fibroblastic foci were induced and 
myofibroblasts differentiation was evident (P.J. Sime, et al., 1997). Currently, TGF-β1 
has been implicated as a major inducer of EMT in lung fibrosis. 
1.2.6 Transcriptional control of EMT 
Numerous pathways have been described in vitro that control phenotype 
transition. In vivo developmental studies suggest that EMT appears to be coordinated and 
is under the tight regulation of transcriptional control. An important component of EMT 
pathway involves activation of key transcription factors (M.A. Huber, et al., 2005, M.A. 
Nieto, 2002, H. Peinado, et al., 2003). Many of the EMT-responsive genes activated by 
these transcription factors encode proteins involved in the induction of EMT, and create 
feedback loops that may help sustain the mesenchymal phenotype (D.C. Radisky, 2005). 
Some models suggest several transcription factors may be key modulators of transitional 
event. 
1.2.6.1 Role of SNAI in EMT 
Recent functional and localization experiments indicate that the SNAI family of 
transcription factors is key EMT contributor, which functions overall as epithelial 
phenotype repressor (P. Savagner, 2001). The Snail superfamily is divided into the SNAI 
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SNAI1 / SNAIL
SNAI2 / SLUG
 Figure 1.8 Comparative scheme of the main structural domains 
found in mammalian SNAI1 and SNAI2. SNAI transcription 
factors have a common organization: highly conserved C-terminal 
containing zinc fingers and a divergent N-terminal SNAG domain. 
The central region of SNAI1 protein has a serine-proline rich 
domain, and a regulatory domain with destruction and nuclear 
export signal boxes. SNAI2 protein contains a SLUG domain in this 
region (H. Peinado, et al., 2007). 
 
and Scratch families, with three members of the SNAI family having been described in 
vertebrates to date: SNAI1, SNAI2 and SNAI3 (A. Barrallo-Gimeno, et al., 2005). 
SNAI1 and SNAI2, also termed as Snail and Slug, respectively, are been well- 
documented as elicitors of EMT in various systems. The role of SNAI3 still remains to be 
elucidated. 
 
 
 
 
 
 
 
 
 
 
 
Members of the SNAI family are zinc finger transcription factors that share a 
common structure: a highly conserved C-terminal region, containing four to six zinc 
fingers (C2H2 type) and a divergent N-terminal region as shown in Figure 1.8. The zinc 
fingers function as the sequence-specific DNA-binding domains that recognize consensus 
E2-box type elements C/A(CAGGTG) (M.A. Nieto, 2002). SNAI factors are currently 
thought to be transcriptional repressors (K. Hemavathy, et al., 2000). Their repressor 
capacity is dependent on the SNAG domain in the N-terminal part of the protein, with 
seven to nine amino acids that are conserved between SNAI and growth factor 
independence (Gfi) proteins. The central region of the SNAI1 protein has a serine–
proline-rich region that is highly divergent between SNAI members. SNAI2 proteins 
contain the so-called slug domain in this region, the function of which remains elusive 
(H. Peinado, et al., 2007). 
By contrast, two different functional domains have been identified in the central 
region of SNAI1 proteins: a regulatory domain containing a nuclear export signal (NES) 
and a destruction box domain (B.P. Zhou, et al., 2004). The post-translational 
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 Figure 1.9 Snail genes occupy a central position in triggering 
EMT in physiological and pathological situations. Different 
signaling molecules have been implicated in the activation of SNAI 
genes in several processes that subsequently lead to EMT. SNAI 
genes, in turn, directly or indirectly regulate the expression of target 
genes (M.A. Nieto, et al., 2002). 
modifications involving phosphorylation of proline/serine residues in both regions and 
potential modification of adjacent lysine residues has been implicated in the subcellular 
localization of SNAI1, protein stability and repressor activity. 
The SNAI1 and SNAI2 genes are highly homologous and in certain circumstances 
can replace each other functionally. For instance, the consequences of SNAI2 knockdown 
in avian embryonic neural crest development can be rescued by transfection of SNAI1 
(M. Sefton, et al., 1998). However, physiologically, they have distinct roles. SNAI1 is 
expressed during mesoderm formation, gastrulation and neural crest development, as well 
as in most developmental processes in which EMT is required. SNAI2 expression has 
been associated with mesoderm and migratory neural crest cells, as well as, in other 
tissues not always associated with EMT. SNAI1 is essential for mouse gastrulation, and 
SNAI1 and SNAI2 for neural crest development in frog and avian embryos, respectively 
(M.A. Neito, 2002). However, they seem not to be essential for mouse neural crest 
formation, but are instead involved in left–right asymmetry (S.A. Murray, et al., 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The initial evidence that a zinc finger protein is involved in the control of EMT 
came from studies of SNAI2 in the chicken embryo. SNAI2 was expressed in chicken 
embryos in epiblast cells lining the primitive streak during gastrulation, as well as in 
neural crest cells just before they emerge from the neural tube, and later during their 
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migration phase. Treatment of developing embryos with antisense oligonucleotides from 
SNAI2 interferes with these two processes, suggesting a potential causal role for SNAI2 
in the EMT process in vivo (P. Savagner, 2001). 
As evident from in vitro and in vivo studies, SNAI transcription factors mediate 
repression of the epithelial phenotype. However, the mechanisms by which they induce 
mesenchymal genes remain largely unknown. It is also known that a plethora of 
molecules can induce SNAI during development (Figure 1.9). SNAI members are now 
thought to be involved in tumor progression, thus having potential clinical interest. The 
specific role of these different repressors in IPF remains to be elucidated. 
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2 Aims of the study 
Recent studies have implicated the occurrence of (1) TGF-β1-mediated EMT in 
alveolar epithelial cells in vitro and in vivo in a triple transgenic mouse model, (2) EMT 
in transgenic mice treated with bleomycin and (3) EMT in lung biopsies from human IPF 
patients. The key molecular mediators regulating EMT are beginning to emerge. The 
contribution of SNAI transcription factors to the development and progression of IPF 
remains to be elucidated. Therefore, the expression of EMT markers and SNAI 
transcription factors were assessed in cell culture, in mouse model of bleomycin-induced 
pulmonary fibrosis and in lung samples from human IPF patients. EMT marker and SNAI 
expression were also determined in kidney samples from a UUO mouse model. In detail, 
the specific aims of this research were: 
1) to assess the occurrence of EMT in vitro in the human A549 alveolar 
epithelial cell line and in primary mouse alveolar type II (AT2) cells, and to 
analyze whether TGF-β1 controls regulatory genes of EMT in these cells, 
2) to analyze the TGF-β1-induced expression and localization patterns of SNAI 
transcription factors, SNAI1 and SNAI2 in vitro, 
3) to determine the occurrence of EMT in vivo, in an experimental mouse model 
of pulmonary fibrosis, and to assess the regulation of SNAI transcription 
factors in vivo, 
4) to assess the occurrence of EMT in human IPF lungs and to determine the 
expression pattern of SNAI transcription factors in context to the disease, 
5) to demonstrate the role of SNAI transcription factors in EMT in alveolar 
epithelial cells by performing functional studies by ectopic expression, as well 
as silencing of SNAI factors in A549 cells, 
6) to assess the occurrence of EMT in vivo in UUO model of neonatal renal 
fibrosis and also to analyze whether EMT and SNAI expression is attenuated 
in UUO animal model by treatment with leukocyte blocker BX471. 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Equipment 
ABI PRISM 7500 Sequence Detection System  Applied Biosystems, USA 
Cell Culture Incubator; Cytoperm2     Heraeus, Germany 
Developing machine; X Omat 2000     Kodak, USA 
Electrophoresis chamber     Bio-Rad, USA 
Film cassette       Sigma-Aldrich, Germany 
Filter Tip FT: 10, 20, 100, 200, 1000    Greiner Bio-One, Germany 
Filter units 0.22 µm syringe-driven     Millipore, USA 
Fluorescence microscope; LEICA AS MDW   Leica, Germany 
Freezer -20 °C      Bosch, Germany 
Freezer -40 °C      Kryotec, Germany 
Freezer -80 °C      Heraeus, Germany 
Fridge +4 °C       Bosch, Germany 
Gel blotting paper 70 × 100 mm     Bioscience, Germany 
Glass bottles: 250, 500, 1000 ml     Fischer, Germany 
GS-800TM Calibrated Densitometer    Bio-Rad, USA 
Laser microbeam system     Palm, Germany 
Light microscope; LEICA DMIL     Leica, Germany 
Mini spin centrifuge       Eppendorf, Germany 
Multifuge centrifuge, 3 s-R      Heraeus, Germany 
Nanodrop®       Peqlab, Germany 
Olympus BX51 microscope     Olympus, Germany 
PCR-thermocycler       MJ Research, USA 
Pipetboy        Eppendorf, Germany 
Pipetmans: P10, P20, P100, P200, P1000    Gilson, France 
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Power Supply; Power PAC 300     Bio-Rad, USA 
Petri dish with vents       Greiner Bio-One, Germany 
Pipette tip: 200, 1000 µl,     Sarstedt, Germany 
Pipette tip 10 µl       Gilson, USA 
Quantity One software     Bio-Rad, USA 
Radiographic film X-Omat LS     Sigma-Aldrich, Germany 
Serological pipette: 5, 10, 25, 50 ml    Falcon, USA 
Test tubes: 15, 50 ml       Greiner Bio-One, Germany 
Tissue culture chamber slides     BD Falcon, USA 
Tissue culture dish 100 mm      Greiner Bio-One, Germany 
Tissue culture flask 250 ml      Greiner Bio-One, Germany 
Tissue culture plates: 6, 24, 48 well    Greiner Bio-One, Germany 
Vortex machine       Eppendorf, Germany 
Western blot chambers:  
Mini Trans-Blot       Bio-Rad, USA 
Mini-Protean 3 Cell       Bio-Rad, USA 
3.1.2 Reagents 
Acetic acid        Merck, Germany 
Acrylamide solution, Rotiphorese Gel 30   Roth, Germany 
Agarose        Invitrogen, UK 
Ammonium persulfate     Promega, Germany 
Ammonium sulfate       Sigma-Aldrich, Germany 
Ampicillin sodium       Sigma-Aldrich, Germany 
β-glycerophosphate      Sigma-Aldrich, Germany 
β-mercaptoethanol       Sigma-Aldrich, Germany 
Bromophenol blue       Sigma-Aldrich, Germany 
Calcium chloride       Sigma-Aldrich, Germany 
CompleteTM Protease inhibitor    Roche, Germany 
DEPC water       Roth, Germany 
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D-(+)-Glucose       Sigma-Aldrich, Germany 
Dimethyl sulfoxide (DMSO)     Sigma-Aldrich, Germany 
Dispase       BD Biosciences, USA 
Dithiothreitol (DTT)      Promega, USA 
D-MEM medium      Gibco BRL, Germany  
DNA Ladder (1 kb)      Promega, USA 
DNase        BD Biosciences, USA 
Dulbecco’s phosphate buffered saline 10×   PAA Laboratories, Austria 
Dulbecco’s phosphate buffered saline 1×   PAA Laboratories, Austria 
Ethylendinitrilo-N, N, N´, N´, -tetra-acetic-acid (EDTA)  Promega, USA 
Ethanol absolute       Riedel-de Haën, Germany 
ECL Plus Western Blotting Detection System  Amersham Biosciences, UK 
Ethidium bromide      Roth, Germany 
Fetal calf serum (FCS)     Gibco BRL, Germany 
Gel extraction kit      Qiagen, Germany 
Glycine       Roth, Germany 
Glycerol        Merck, Germany 
GoTaq® Flexi DNA Polymerase    Promega, USA 
Heparin       Merial GmbH, Germany 
Hydrochloric acid       Sigma-Aldrich, Germany 
2-(-4-2-hydroxyethyl)-piperazinyl-1-ethansulfonate  
(HEPES)       Sigma-Aldrich, Germany 
Lipofectamine       Invitrogen, UK 
Isotonic sodium chloride solution    Delta Select, Germany 
Luria-Bertani Medium      Invitrogen, UK 
Magnesium chloride       Sigma-Aldrich, Germany 
Magnesium sulfate       Sigma-Aldrich, Germany 
Methanol        Fluka, Germany 
MiniElute Gel Extraction Kit     Qiagen, Germany 
M-MLV reverse transcriptase    Promega, USA 
Narcoren       Merial GmbH, Germany 
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N,N,N',N'-tetramethyl-ethane-1,2-diamine (TEMED) Bio-Rad, USA 
Nitro-cellulose membrane     Bio-Rad, USA 
Non-fat dry milk powder     Roth, Germany 
Oligo(dT)15 Primer      Promega, USA 
Opti-MEM medium       Gibco BRL, Germany 
PCR Nucleotide Mix      Promega, USA 
Penicillin-streptomycin     PAA Laboratories, Austria 
Platinum SYBR Green qPCR SuperMix UDG  Invitrogen, UK 
Potassium acetate       Sigma-Aldrich, Germany 
Potassium chloride       Merck, Germany 
Potassium phosphate       Sigma-Aldrich, Germany 
Precision Plus ProteinTM Standards     Bio-Rad, USA 
2-Propanol        Merck, Germany 
Pure Yield Plasmid Midiprep System   Promega, Germany 
QIAprep Spin Miniprep Kit     Qiagen, Germany 
Quick StartTM Bradford Dye Reagent   Bio-Rad, USA 
Restriction endonucleases     Promega, Germany 
RNAsin inhibitor      Promega, Germany 
RNaseZAP       Sigma-Aldrich, Germany 
RNeasy Midi Kit      Qiagen, Germany 
Select agar        Invitrogen, UK 
Sodium acetate       Sigma-Aldrich, Germany 
Sodium chloride       Merck, Germany 
Sodium dodecyl sulfate (SDS)     Promega, USA 
Sodium ortho vanadate     Sigma-Aldrich, Germany 
Sodium phosphate       Sigma-Aldrich, Germany 
Sodium sulfate       Merck, Germany 
SuperSignal® West Pico Chemiluminescent Substrate Pierce, USA 
Taq DNA polymerase     Invitrogen, Germany 
T4 DNA ligase       Promega, Germany 
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TGF-β1       R&D Systems, USA 
Tris         Roth, Germany 
Triton X-100        Promega, USA 
Trypsin/EDTA       Gibco BRL, Germany 
Tween 20        Sigma-Aldrich, Germany 
Histostain-SP Kit      Zymed, USA 
3.2 Animal Tissues 
All animal studies were performed in accordance with the guidelines of the Ethic 
Committee of University of Giessen School of Medicine and approved by the local 
authorities (Regierungspräsidium Giessen, no. II25.3–19c20–15; GI20/10-Nr.22/2000). 
All animal studies utilized pathogen-free adult male C57BL/6N mice (18-20 g). After 
administration of bleomycin or saline, all mouse tissues were surgically excised, washed 
in ice-cold 1 x PBS and frozen in liquid nitrogen for further analyses. AT2 cells were also 
isolated from mice treated with or without bleomycin. 
3.3 Human Tissues 
Lung tissue biopsies were obtained from twelve patients with IPF (mean age 51 ± 
11 years; six females, six males) and nine control subjects (mean age 48 ± 14 years; five 
females, four males). The study protocol was approved by the Ethics Committee of the 
University of Giessen School of Medicine (AZ 31/93). Informed consent was obtained 
from each subject for the study protocol.  
3.4 Methods 
3.4.1 Mammalian cell culture 
3.4.1.1 A549 cells 
The human lung carcinoma alveolar epithelial cell line A549 (ATCC CCL-185; 
Manassas, VA, USA) was propegated in tissue culture flasks in D-MEM medium 
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supplemented with 10% (v/v) heat-inactivated FCS at 37 °C, 5% CO2, 95-100% 
humidity. The cell line was passaged when it attained 80-90% confluence. During 
passaging, cells were washed with 1 × PBS and incubated with 3 ml of Trypsin/EDTA 
solution for 3 min at 37 °C, after which 7 ml of D-MEM medium was added. Cells were 
transferred to new tissue culture flasks after 1:5 dilution with medium.  
3.4.1.2 Isolation of alveolar epithelial type II (AT2) cells  
Primary mouse alveolar epithelial type II (AT2) cells were isolated from adult 
male C57BL/6N mice, by dispase disaggregation followed by differential adherence on 
IgG coated petriplates and cultured as previously described (M. Corti, et al., 1996, I. 
Vadasz, et al., 2005).  
Briefly, mice were sacrificed by intraperitoneal injection of a mixture of narcorin 
and heparin (1:1:1 - Narcorin:heparin:saline in a final volume of 200 µl). The thoracic 
cavity was opened carefully to avoid puncturing the lung. The trachea was exposed by a 
midline neck incision and a catheter was inserted and ligated. The abdomen was opened, 
the renal artery was separated and pneumothorax was drawn. Afterwards, lungs were 
perfused with saline and lavaged. Next, the proteolytic enzyme dispase (1.2 ml) was 
instilled via trachea to release AT2 cells. This was followed by low-melting-point agarose 
instillation (0.4 ml), maintained in liquid form at 55 °C. Agarose solution was allowed to 
solidify for 2 min inside the lungs and the respiratory organs were then separated from 
the thorax and incubated in 1.5 ml Dispase solution for 45 min at room temperature. After 
this incubation period, lung tissue was transferred into Petri dish with DNase containing 
Plus Medium and was gently teased with forceps to aid cell separation. This was followed 
by subsequent washes with Plus Medium and filtration through 100 µm, 20 µm and        
10 µm nylon mesh filters and centrifuged at 130 g for 10 min to collect cells and exclude 
debris. The resulting pellets were dispersed with Minus Medium.  
  Minus Medium  
500 ml D-MEM 
10 mM HEPES 
1% Pen-strep 
1.8 g Glucose 
2% L-Glutamine 
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Plus Medium 
Minus Medium with 0.04 mg/ml DNase 
 
Following dispase disaggregation, a purification method based on the differential 
adherence of immune cells and other contaminating cells to IgG-coated Petri dishes was 
performed. Petri dishes were coated with a mixture of CD45 (20 µl/dish) and CD16/32 
(15 µl/dish) antibodies diluted in Minus Medium, and incubated overnight at 4 °C, to 
allow the antibodies to adhere to the Petri dishes. The cell suspension was first incubated 
on mouse IgG-coated dishes for 45 min for attachment of contaminating cells bearing Fc 
receptors. This was followed by a 30 min incubation of the cell suspension, containing 
unattached cells, on uncoated Petri dishes for the attachment of fibroblasts. The 
unattached cells, mainly comprising of AT2 cells, were then collected and a cell count 
was performed using Nile Red staining, which identifies lamellar bodies, a characteristic 
organelle in AT2 cells. Briefly, the Nile Red staining was performed as follows: 20 µl of 
cell suspension was dispensed in 500 µl D-MEM containing a 1:20 dilution of Nile Red 
solution. The mix then was vortexed and incubated for 5 min at room temperature. 
Stained cells were counted under UV-light.  
Freshly isolated cells were immunocytochemically tested for contaminating cells. 
Macrophages, lymphocytes and endothelial cells were not detected upon 
immunofluorescence analysis using CD45 and vWF antibodies. Such cultures were used 
for subsequent experiments. The AT2 pneumocytes were plated either on dishes (1 X 106 
cells/ml) or on chamber slides (90,000 cells/well) in Minus Medium supplemented with 
10% FCS. Cells were subjected to serum starvation before treatment with TGF-β1. Only 
AT2 cells up to day 3 were used in this study. All cultures were maintained in humidified 
atmosphere with 5% CO2 at 37 °C, the media was changed every other day.  
3.4.2 RNA isolation 
In order to isolate RNA from cell culture and tissue samples, two alternative 
methods were applied.  
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3.4.2.1 RNA isolation from cultured cells 
Using RNeasy Mini Kit, RNA was isolated from A549 cells and freshly isolated 
AT2 cells according to the manufacturer’s instructions. 
3.4.2.2 RNA isolation from lung homogenates 
Human and mouse lung tissue were ground to powder under liquid nitrogen with a 
mortar and pestle, and total RNA was extracted using Roti-Quick Kit. Guanidinium 
isothiocyanate was added to the tissue to isolate RNA, which was separated from the 
sheared DNA and proteins by adding phenol/chloroform, and precipitated overnight with 
isopropanol. Further steps were performed according to the manufacturer’s protocol.  
3.4.3 Determining RNA and DNA concentration 
The concentration of isolated RNA or DNA was determined according to a 
protocol from Peqlab by applying 1.5 µl of the sample to a 
Nanodrop spectrophotometer. 
3.4.4 Reverse transcription reaction 
Reverse Transcription Polymerase Chain Reaction (RT-PCR) is a reverse 
transcriptase (RT)-driven enzymatic reaction, which generates complementary DNA 
(cDNA) using mRNA as a template.  
In order to perform RT-PCR, 500 ng of total RNA was added to 1 µl of oligo-
(dT)15 (100 µg/ml) primers, and mixed with RNAse free water to a final volume of 10 µl 
in a PCR tube. The mix was heated at 70 °C for 5 min. The reaction was cooled on ice for 
5 min to allow annealing of Oligo(dT)15 to the poly A tail of the mRNA and the master-
mix of the following RT-reaction reagents were added. 
The reaction was performed at 42 °C for 60 min and completed at 70 °C for          
5 min. The resulting complementary DNA (cDNA) was further used for polymerase 
chain reaction or stored at -20 °C. 
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Table 3.1 RT reaction master mix 
 
Components Volume Final 
concentration 
5× RT Buffer 5 µl 1 × 
10 mM dNTP mix 0.5 µl 0.2 mM 
RNAsin inhibitor (1 U/µl)  0.5 µl 0.5 U 
MMLV Reverse transcriptase  
(1 U/µl) 
0.5 µl 0.5 U 
RNAse free water 8.5 µl not applicable 
3.4.5 Polymerase chain reaction 
Polymerase chain reaction (PCR) is a DNA polymerase driven enzymatic 
reaction, which permits the amplification of selected fragments of genomic DNA. 
Product specificity is determined by the DNA primers used in the reaction.  
3.4.5.1 Semi-quantitative PCR 
The reaction was performed according manufacturer’s protocol from Go Taq® 
Flexi DNA polymerase kit, and all components were combined as follows and the final 
volume was adjusted with distilled, autoclaved water upto 50 µl. 
Table 3.2 PCR reaction master mix 
 
Components Volume 
 
Final 
concentration 
5× PCR Buffer (free MgCl2 free) 10 µl 1 × 
10 mM dNTP mix 1 µl 0.2 mM 
25 mM MgCl2 2 µl 1 mM 
10 µM forward primer 1 µl 0.2 mM 
10 µM reverse primer 1 µl 0.2 mM 
DNA template 1 µl not applicable 
GoTaq® Flexi DNA polymerase 
(5U/µl) 
0.25 µl  1.25 U 
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This reaction mix is transferred to a PCR thermal cycler and denatured for 5 min 
at 95 °C. The PCR process was carried out for appropriate cycle numbers as indicated in 
Table 6.1 and 6.2 with appropriate primers. Each PCR cycle consists of three steps: 
denaturation (separation of double-stranded DNA), annealing (binding of primers to 
specific region of DNA), and elongation (extending of generated product). The steps 
were carried out as follows: 
Table 3.3 PCR program 
Step Temperature Duration 
First denaturation 95 °C 5 min 
Second denaturation 95 °C 45 s 
Annealing 58-62 °C 30 s 
Extension 72 °C 1 min 
Final extension 72 °C 10 min 
 
The reaction was completed by a final extension step at 72 °C for 10 min. The 
sample was further analyzed by DNA gel electrophoresis or stored at -20 °C.  
3.4.5.2 Real-time PCR 
Real-time RT-PCR is a variation of the conventional PCR and allows the 
simultaneous amplification and quantification of specific DNA fragments. The reaction 
mix of real-time RT-PCR includes a fluorescent dye (e.g. Syber Green) that intercalates 
with the newly synthesized double-stranded DNA during the PCR reaction, resulting in 
increased fluorescence intensity detected after each cycle. The level of fluorescence is 
proportional to the amount of amplified DNA. 
The reaction was performed according to a protocol from the Syber® Green PCR 
kit using a Sequence Detection System 7500 Fast from Applied Biosystems. All 
components were combined as follows and the final volume was adjusted to 25 µl with 
distilled, autoclaved water and the real-time PCR was performed for 45 cycles as follows, 
using the appropriate primers indicated in Table 6.3 and 6.4. 
 
 
Materials and Methods  31 
 
Table 3.4 Real-time PCR master mix: 
 
Components Valume Final 
concentration 
Platinum® Syber® Green qPCR 
SuperMix-UDG 
13 µl 1 × 
50 mM MgCl2 1 µl 2 mM 
10 µM forward primer 0.5 µl 0.2 mM 
10 µM reverse primer 0.5 µl 0.2 mM 
DNA template 1 µl not applicable 
 
Table 3.5 Real-time PCR program 
 
Step Temperature Duration 
Activation of polymerase enzyme 50 °C 2 min 
First denaturation 95 °C 5 min 
Second denaturation 95 °C 5 s 
Annealing 59 °C 5 s 
Extension 72 °C 30 s 
Dissociation step 1 95 °C 15 s 
Dissociation step 2 60 °C 1 min 
Dissociation step 3 95 °C 15 s 
Dissociation step 4 60 °C 15 s 
 
The gene expression was analyzed by 7500 Fast System Software. All results 
were normalized to the relative expression of the constitutively-expressed 
porphobilinogen deaminase (PBGD) gene. The relative transcript abundance of the target 
gene is expressed in ∆Ct values (∆Ct=Ct reference - Ct target). Relative changes in 
transcript levels compared to controls are expressed as ∆∆Ct values (∆∆Ct=∆Ct treated - 
∆Ct control). All ∆∆Ct values correspond approximately to the binary logarithm of the 
fold-change. The specific amplification of the PCR products was confirmed by melting 
curve analysis and gel electrophoresis. 
 
Materials and Methods  32 
 
3.4.6 Protein isolation 
In order to isolate proteins from cell culture and tissue samples, two alternative 
methods were applied.  
3.4.6.1 Protein isolation from cell culture 
In order to isolate proteins, confluent monolayers of cells were washed twice with 
ice-cold 1 × PBS. PBS buffer was applied to cell monolayers (100 µl/cm2), and cells were 
detached by scraping, and transferred to 1.5 ml tubes. After centrifugation for 3 min at 
3000 g, the pellet was resuspended in 100 µl of cell-lysis buffer. The cell lysate was 
incubated for 30 min on ice and centrifuged at 16000 g for 15 min. The resulting 
supernatant was used as a crude cell extract, and stored at -20 °C. 
 
1 × PBS, pH 7.4: 
0.02% (w/v) KCl 
0.115%  (w/v) Na2HPO4 · 2H2O 
0.02% (w/v) KH2PO4 · 2H2O 
 
Cell-lysis buffer: 
20 mM Tris-HCl, pH 7.5 
150 mM NaCl 
1 mM EDTA 
1 mM EGTA 
0.5% Igepal CA-630 
2 mM Na3VO4 * 
Complete™, protease inhibitor mix * 
*Added immediately prior to homogenization 
3.4.6.2 Protein isolation from tissue 
Human or mouse tissue was homogenized in liquid nitrogen and ice-cold tissue 
lysis buffer was added. Tissue lysate was then passed three times through a 0.9 mm 
needle fitted to a RNase-free syringe. Homogenized tissue was incubated for 1 h on ice 
and centrifuged for 15 min at 16000 g. The resulting supernatant was used as a crude 
tissue extract and stored at –20 °C. 
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Tissue lysis buffer: 
20 mM Tris-HCl, pH 7.5 
150 mM NaCl 
1 mM EDTA 
1 mM EGTA 
1% (v/v) Triton X-100 
2 mM Na3VO4 * 
Complete™, protease inhibitor mix * 
*Added immediately prior to homogenization 
3.4.7 Gel electrophoresis 
The length and purity of nucleic acids (DNA, RNA) is routinely determined 
accurately by gel electrophoresis method. This method also allows separation of proteins 
based on their physical properties such as, size and electric charge. 
3.4.7.1 DNA gel electrophoresis 
For preparation of 1% agarose gels, agarose was dissolved in 1 × Tris-acetate-
EDTA (TAE) buffer containing 0.5 µg/ml ethidium bromide, a fluorescent intercalating 
dye. DNA samples were mixed 5:1 with 6 × agarose gel-loading buffer and loaded onto 
the gel. Electrophoresis was performed for 1 h at 100 V, in 1 × TAE buffer. Separated 
nucleic acids were visualized with short wavelength UV-light (λ 257 nm).  
1 × TAE buffer:  
40 mM Tris acetate, pH 8.0 
1 mM EDTA, pH 8.0 
 
6 × agarose gel-loading buffer: 
0.025% (w/v) bromophenol blue 
40% (w/v) sucrose 
3.4.7.2 Protein gel electrophoresis 
The denaturating SDS polyacrylamid gel electrophoresis (SDS-PAGE) was used 
to separate proteins electrophoretically according to their molecular weight. The 10% 
resolving gel mixture was poured between two glass plates with spacers between, and 
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allowed to polymerize. The stacking gel was poured on top of the resolving gel, and a 
comb was inserted into the gel to form wells. Prior to loading on the gel, samples were 
mixed with 10 × SDS gel-loading buffer and heated at 95 °C for 7 min. Electrophoresis 
was carried out in 1 × SDS-running buffer at 120 V for 1 h. 
5% stacking gel: 
5% acrylamide/bisacrylamide 
125 mM Tris-HCl, pH 6.8 
0.1% SDS (w/v) 
0.1% APS (w/v) 
0.1% TEMED (v/v) 
 
10% resolving gel: 
10% acrylamide/bisacrylamide 
375 mM Tris-HCl, pH 8.8 
0.1% SDS (w/v) 
0.1% APS (w/v) 
0.1% TEMED (v/v) 
 
10 × SDS-loading buffer: 
625 mM Tris-HCl, pH 6.8 
50% (v/v) glycerol 
20% (w/v) SDS 
9% (v/v) β-mercaptoethanol 
0.3% (w/v) bromophenol blue 
 
1 x SDS running buffer: 
25 mM Tris 
250 mM Glycine 
0.1% (w/v) SDS 
0.08% (w/v) NaCl 
3.4.8 Western blot analysis 
Western blotting is a protein detection method and allows identification of 
specific proteins by exposing all proteins present on gel to a specific antibody. 
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3.4.8.1 Western blotting 
Proteins resolved by SDS-PAGE were transferred from a polyacrylamide gel to a 
polyvinylidene difluoride (PVDF) or nitrocellulose membrane. In case of PVDF, it was 
first activated in 100% methanol. Protein transfer was performed in transfer buffer at   
100 V for 1 h. 
Transfer buffer (pH 7.4): 
24 mM Tris 
193 mM glycine 
10% (v/v) methanol 
3.4.8.2 Protein visualization 
The membrane was incubated in blocking solution for 1 h at room temperature 
followed by incubation with appropriate primary antibodies in blocking buffer at 4 °C 
overnight. The membrane was then washed three times with washing buffer and 
incubated with horseradish proxidase (HRP) labeled secondary antibodies for 1 h at room 
temperature. The membrane was washed five times for 10 min. Proteins were detected 
using chemiluminescence by Enhanced Chemiluminescent Immunoblotting System and 
membrane was exposed to radiographic film. 
Blocking buffer: 
5% (w/v) non-fat dry milk 
1 × PBS 
0.1% (v/v) Tween 20 
 
Washing buffer: 
1 × PBS 
0.1% (v/v) Tween 20 
 
Stripping buffer: 
62.5 mM Tris-HCl, pH 6.8 
2% (w/v) SDS 
100 mM β-mercaptoethanol 
 
For subsequent applications of different secondary antibodies, the membrane was 
incubated in stripping buffer for 10 min and washed repeatedly and protein visualization 
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was performed as previously described. Primary and secondary antibodies are listed in 
Tables 6.6 and 6.7. 
3.4.9 Immunohistochemistry 
To localize and assess the expression of particular proteins in human and mouse 
lung sections, immunohistochemical analysis was performed using a standardized 
avidin/biotin detection system (Histostain-SP Kit). At first, formalin-fixed paraffin-
embedded tissue sections (3 µm thickness) were incubated overnight at 48 °C and 
deparaffinized in xylene. After rehydration, using a stepwise decreasing ethanol 
concentration gradient (100% to 70%), antigen retrieval was performed in citrate buffer 
(pH 6.0) for 20 min at 100 °C. Slides were washed two times for 5 min in 1 × PBS. 
Endogenous peroxidase activity was quenched with 1% (v/v) H2O2 for 20 min. Slides 
were blocked with serum blocking solution for 1 h at room temperature and incubated 
with the respective primary antibody (Table 6.6) at desired concentration overnight at      
4 °C. The following day slides were incubated with biotinylated secondary antibody 
(Table 6.7) for 10 min at room temperature and subsequently 100 µl of a substrate 
chromogen mixture was added to each section. Slides were developed for 5 min with 
AEC and counterstained with Mayers hematoxylin. Finally, sections were covered in 
glycergel and cover-slide was mounted and evaluated using an Olympus BX51 
microscope.  
3.4.10 Immunofluorescence 
This method identified localization of particular proteins in cells by using 
fluorescent dyes. Cells were plated on 8-well chamber slides, incubated in the absence or 
presence of TGF-β1 (2 ng/ml) for 24 h, and fixed with ice-cold methanol. After blocking 
nonspecific binding sites with 5% FBS in PBS, cells were incubated with primary 
antibodies (Table 6.6) at 4 °C overnight, washed three times in PBS and incubated with 
Fluorescein isothiocyanate (FITC) and or Alexa Fluor 546-labelled secondary antibodies 
(Table 6.7). Cells were washed again five times with PBS. The plastic border of the slide 
was removed and slides were covered with mounting medium and a cover slide. Nuclei 
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were visualized by 4’6-diamidino-2-phenylindole staining (DAPI). The staining was 
analyzed by deconvolution fluorescence microscope.  
3.4.11 Laser-assisted microdissection 
In brief, 10 µm cryosections were mounted on glass slides, stained with hemalaun 
for 45 s, immersed in 70% and 96% ethanol, and stored in 100% ethanol until use. 
Alveolar septae were selected and microdissected with a sterile 30 G needle under optical 
control using the Laser Microbeam System. Microdissected tissues were transferred into 
reaction tubes containing 200 µl RNA lysis buffer and samples were processed for RNA 
analysis. 
3.4.12 Cloning and transfection of human SNAI1 and SNAI2 
The human SNAI1 expression construct was generated by amplifying full-length 
SNAI1 cDNA from total A549 RNA by PCR. SNAI1 cDNA was cloned into a 
mammalian expression vector, pcDNA3.1(-). SNAI2 expression construct was obtained 
form Origene, USA. SNAI1 and SNAI2 were transiently transfected into A549 cells and 
the effect of their ectopic expression were analysed.  
3.4.12.1 PCR product purification 
To subclone SNAI gene into an expression vector, the DNA template was 
analysed for the appropriate restriction sites (BamH1 and Xho1) using the DNA Star 
software and appropriate primers were designed. Full-length SNAI1 cDNA was amplified 
from total lung RNA by PCR using the forward and reverse primers 5´- CAG TGC CTC 
ACC ACT ATG C-3´ and 5´- AGG ATC CTC GAG GGT CAG-3´, respectively. The 
amplified DNA fragment was analyzed and separated by agarose gel electrophoresis, 
excised and gel-purified using a commercially available gel extraction kit according to 
the manufacturer’s protocol.  
3.4.12.2 Ligation of PCR products into pGEM-T Easy vector 
The purified PCR product was ligated into pGEM-T Easy vector using the 
following ligation mix:  
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Table 3.6 Ligation mix 
Components Volume 
2 X rapid ligation buffer 5 µl 
pGEMT-T Easy Vector (50 ng) 1 µl 
Purified PCR product Depends on DNA 
concentration 
T4 DNA ligase 1 µl 
Autoclaved, deionized water up to 10 µl 
 
This reaction mix was incubated overnight at 4°C.  
3.4.12.3 Transformation and amplification of plasmids 
 After ligation, plasmids were transformed in competent E. coli DH5α for further 
amplification. 1 µg of plasmid DNA was added to 50 µl of competent bacteria and the 
samples were incubated on ice for 30 min. Cells were then subjected to heat shock for     
1 min in a 42 °C water bath, and snap chilled for 2 min on ice. 400 µl of LB medium was 
added and the tube was shaken for 15 min at 37 °C at 250 rpm. X-Gal and IPTG were 
added to the LB medium and then plated on LB plates (LB medium plus 1.5% agar) 
containing appropriate antibiotics. After overnight incubation of the plates at 37 °C, 
individual bacterial colonies were picked from the plate on the following day and 
inoculated in LB medium containing the appropriate antibiotics. The bacterial tubes were 
shaken overnight at 37 °C at 250 revolutions per minute (rpm). Plasmids were 
subsequently isolated using Qiagen plasmid isolation kit. 
3.4.12.4 Subcloning into mammalian expression vectors 
 In order to subclone SNAI1 from pGEM-T Easy vector into a mammalian 
expression vector, pcDNA3.1(-), both empty expression vector and pGEM-T Easy 
plasmid, containing the human SNAI1 PCR product, were digested with the same 
restriction enzymes for 1-3 h at 37 °C, separated by agarose gel electrophorsis and gel-
purified. The purified PCR product and the linearized purified vector were ligated in the 
ratio 3:1 with T4 DNA ligase and incubating 30 min at room temperature. The following 
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steps were performed as described in the previous chapter (3.4.12.3). All the SNAI1 
constructs used were verified by sequencing.  
3.4.12.5 Transfection of A549 cells 
Transient transfection of plasmids is a technique to transfer DNA into eukaryotic 
cells. This method is transient as the transfected DNA is not integrated into the host 
chromosomes. SNAI1 and SNAI2 were transiently transfected into A549 cells using 
LipofectamineTM2000 reagent. Briefly, Lipofectamine was added to OptiMEM, vortexed 
for 30 s, and incubated at room temperature for 5 min. Two micrograms of SNAI 
plasmids were added at a 1:3 DNA:Lipofectamine ratio in OptiMEM, incubated for       
30 min at room temperature and added to the cells. 24 h and 48 h post-transfection, cells 
were harvested and RNA and protein was isolated for further analysis. 
3.4.13 siRNA transfection 
The siRNA oligonucleotides specific for human SNAI1 and SNAI2 mRNA (Table 
6.5) were obtained from Dharmacon Inc. (Lafayette, USA). A549 cells were transiently 
transfected with 100 nM SNAI or non-specific siRNA using LipofectamineTM2000 
reagent. Briefly, Lipofectamine was added to OptiMEM and incubated for 15 min. 
siSNAI or non-specific siRNA was added to OptiMEM, and this mix was transferred into 
Lipofectamine and OptiMEM mix after 15 min. The mix was incubated for another       
15 min at room temperature with constant shaking. Afterwards the siRNA mix was added 
to the cells and 4 h post transfection, cells were treated with TGF-β1. Cells were lyzed 
after 24 h and efficiency of gene knockdown was monitored.  
3.4.14 Migration assay  
Cell migration was determined using Boyden chamber assay (ThinCertsTM Tissue 
Culture Inserts, 24 well, pore size 3.0 µm from Kremsmunster, Austria). A549 cells were 
transfected with SNAI1, SNAI2 or non-specific siRNA at a total concentration of 75 nM, 
detached, and 5 × 104 cells were seeded into Boyden chamber insert. Cells were cultured 
for 8 h to allow their attachment to the membrane and migration was induced by adding 
TGF-β1 (2 ng/ml) to the media in the lower wells. After 24 h, cells were fixed and 
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stained using crystal violet solution, and non-migrated cells were removed by cotton 
swabbing. The membranes were carefully separated from the insert wall, and optical 
densities of migrated cells were measured with a GS-800 Calibrated Densitometer and 
analysed with the Quantity One software.  
3.4.15 Experimental model of idiopathic pulmonary fibrosis 
Bleomycin is an anticancer agent and a single administration in mice, causes 
pathologic alterations in the lung that mimicks human IPF. The bleomycin mouse model 
of IPF is one of the most widely used animal models of IPF. 
Bleomycin sulfate was dissolved in sterile saline solution and was applied to adult 
male C57Bl/6 mice as a single dose (0.08 mg/mouse in a total volume of 200 µl) by 
intratracheal instillation using a microsprayer. Control mice received 200 µl saline. Mice 
were sacrificed after 7, 14, or 21 days, as indicated. AT2 cells were isolated from these 
mice lungs or lungs were inflated with 4% (w/v) paraformaldehyde in phosphate buffered 
saline at 21 cm H2O pressure and processed for histological analyses, or excized, snap 
frozen in liquid nitrogen, and processed for molecular biological analyses. 
3.4.16 Experimental model of renal fibrosis 
This experiment was performed in collaboration with Sperandio et al., (B. Lange-
Sperandio, et al., 2007) and animal experiments were performed in Heidelberg and RNA 
samples from kidney was provided for EMT marker analysis. Briefly, two-day-old wild-
type mice (C57BL/6) were distributed into four groups (n = 16 in each group) receiving 
subcutaneous injections of either BX471 (Berlex Biosciences, Richmond, CA) at         
100 mg/kg body weight per day dissolved in propylene glycol (vehicle) for 5 (days 2 to 7 
of life) or 12 (days 2 to 14 of life) days, or vehicle, once daily. BX471 was dissolved in 
propylene glycol (no. 39,803-9, 1,2-propanediol; Aldrich, Seelze, Germany) at a 
concentration of 25 mg/ml. Mice were subjected to complete left ureteral obstruction or 
sham operation under general anesthesia with isoflurane and oxygen at the second day of 
life. After recovery, neonatal mice were returned to their mothers until sacrificed 5 and 
12 days after surgery (at days 7 and 14 of life; n = 8 per group). The experimental 
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protocol was approved by the Committee for Animal Experimentation of the University 
of Heidelberg. 
3.4.17 Statistical analysis of data 
Values are presented as mean ± SEM. The mean of indicated groups were 
compared using two-tailed Student´s t-test or a 1-way analysis of variance (ANOVA) 
with Tukey HSD post hoc test for studies with more than two groups. A level of p<0.05 
was considered statistically significant. All experiments were performed at least three 
times. 
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 Figure 4.1 Purity of primary alveolar epithelial type II (AT2) 
cells. Expression and localization of proSP-C, Tjp1 and α-SMA in 
freshly isolated mouse AT2 cells and two and three days after 
plating was determined by immunofluorescence analysis. Nuclei 
were analyzed by 4’6-diamidino-2-phenylindole (DAPI) staining. 
Original magnification is 20×. 
 
4 Results 
4.1 Analysis of EMT in vitro  
4.1.1 Estimation of the purity of primary mouse AT2 cells 
Various cellular markers were used to assess the purity of isolated mouse AT2 
cells. Freshly isolated, as well as primary AT2 cells cultured for up to three days 
routinely exhibited a purity of >95%, as assessed by immunofluorescence analysis of 
cells positive for the AT2 cell marker proSP-C, epithelial marker Tjp1 and fibroblast 
marker α-SMA.  
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 Figure 4.2 Expression of TGF-β1 signaling components in AT2 
cells. Expression analysis of Smad2-4, Smad6-7, ALK1, ALK5, 
TβRII, and GAPDH was performed by RT-PCR on whole lung 
RNA derived from two different mice (lanes 1, 2), and from two 
different primary AT2 cell preparations (lanes 3, 4). TβRII 
amplification reveals the two known isoforms of this receptor. 
Product sizes are indicated to the right of the PCR panel. 
A large number of cells stained positive for proSP-C and Tjp1 immediately after 
isolation and plating, as well as two and three days after plating, whereas very few cells 
stained positive for α-SMA as depicted in Figure 4.1. 
4.1.2 Expression of TGF-β1 signaling components in primary 
mouse AT2 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To analyze whether TGF-β1 treatment of primary AT2 cells resulted in EMT, 
initially the expression of various TGF-β signaling components was assessed. The    
TGF-β signaling components, namely the TGF-β type I receptors (ALK1, ALK5), TGF-β 
type II receptor (TβRII), TGF-β-activated Smads (Smad2, Smad3, and the common 
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 Figure 4.3 EMT marker localization and expression in primary 
AT2 cells. Immunofluorescence detection of α-SMA, E-cadherin, 
and Tjp1 was performed after treatment with TGF-β1 (2 ng/ml) or 
vehicle for 24 h. Co-localization of α-SMA (red) and Tjp1 (green) 
was assessed by immunofluorescence in AT2 cells treated with 
TGF-β1 for 24 h. Nuclei were visualized by 4’6-diamidino-2-
phenylindole (DAPI) staining. Original magnification is 63×.  
 
Smad4), and inhibitory Smads (Smad6 and Smad7) were examined by semi-quantitative 
RT-PCR analysis in RNA from isolated AT2 cells, as well as total mouse lungs. 
When comparing RNA levels in total mouse lung homogenates (Figure 4.2, lanes 
1, 2) with primary mouse AT2 cells (Figure 4.2, lanes 3, 4), a lower expression level of 
ALK1 in AT2 cells compared with homogenates was observed. All other genes were 
expressed and exhibited equal expression in total mouse lung homogenates and AT2 
cells. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as a loading control.  
4.1.3 EMT marker localization in primary mouse AT2 cells 
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 Figure 4.4 Expression of mesenchymal marker α-SMA in AT2 
cells. Panel (A) depicts the quantification of the percentage of
α-SMA-positive cells 24 h after TGF-β treatment (2 ng/ml). (B) 
Original magnification of the representative figure showing 
immunofluorescence detection of α-SMA with TGF-β1 (2 ng/ml) or 
vehicle for 24 h is 10×. Data are expressed as mean ± SE; * p<0.05, 
n = 10. 
 
 
As depicted in Figure 4.3, TGF-β1 treatment in AT2 cells for 24 h induced 
changes in α-SMA, E-cadherin, and Tjp1 (zona occludens-1) expression and/or 
localization indicative of EMT. Epithelial markers, E-cadherin and Tjp1 staining 
decreased in TGF-β1-treated cells. In contrast, the mesenchymal marker α-SMA staining 
increased in TGF-β1-treated cells compared with vehicle treated cells. While these 
changes in EMT marker staining strongly suggested the occurrence of EMT in primary 
mouse AT2 cells, this was unequivocally demonstrated by α-SMA and Tjp1 double-
positive cells in TGF-β1-treated, but not vehicle-treated cells (Figure 4.3, bottom panels). 
4.1.4 Mesenchymal marker expression in primary mouse AT2 cells 
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 Figure 4.5 EMT marker gene expression in primary AT2 cells.
Using semi-quantitative (A) and real-time RT-PCR (B) analysis, the 
expression patterns of the indicated EMT markers was detected in 
primary mouse AT2 cells, after TGF-β1 treatment for 2 and 8 h, as 
indicated. Data are expressed as mean ± SEM; * p<0.05, n = 5.  
Subsequently, the increase in mesenchymal marker α-SMA expressing cells 24 h 
post TGF-β1 treatment was quantified. The number of α-SMA-positive cells clearly 
increased in TGF-β1-treated cells from 5.9 ± 2.8 % to 28.2 ± 8.1% in untreated and      
TGF-β1-treated cells, respectively (Figure 4.4).  
4.1.5 EMT marker gene expression in primary mouse AT2 cells 
 
 
 
 
 
 
 
Next, the mRNA expression patterns of several EMT marker genes were 
evaluated by semi-quantitative and real-time RT-PCR analysis, with the aim of 
identifying crucial mediators of EMT that, if depleted by experimental manipulation, 
could lead to a reduction in EMT. As depicted by semi-quantitative RT-PCR, (Figure 
4.5A), when primary mouse AT2 cells were grown in the presence of TGF-β1 for 2 and   
8 h, a decrease in the expression of the epithelial markers E-cadherin and occludin, and 
an increase in mesenchymal marker vimentin was observed. No change in the expression 
of α-SMA was detected. An increase in SNAI1 and SNAI2 expression was also detected. 
A significant increase in SNAI1 and SNAI2 gene expression was evident in AT2 cells 
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 Figure 4.6 EMT marker gene expression in A549 cells. Using 
semi-quantitative (A) and real-time RT-PCR (B) analysis, the 
expression patterns of the indicated EMT markers was detected in 
A549 cells, after TGF-β1 treatment for 2 and 8 h, as indicated. Data 
are expressed as mean ± SEM; * p<0.05, n = 5.  
(Figure 4.5B) treated with TGF-β1 for 2 and 8 h. An increase in the expression of 
vimentin and α-SMA and concomitant decrease in the expression of E-cadherin and 
occludin mRNA was observed by real-time RT-PCR. 
4.1.6 EMT marker gene expression in the human A549 cell line 
Immortalized A549 cells are a model cell-line routinely used in place of primary 
AT2 cells. In order to confirm the occurrence of TGF-β1-mediated EMT in A549 cells, 
the mRNA expression patterns of several EMT marker genes was investigated using 
semi-quantitative and real-time RT-PCR analysis. As depicted in Figure 4.6, 
downregulation of occludin and upregulation of α-SMA, SNAI1 and SNAI2 was 
observed by semi-quantitative PCR, upon TGF-β1 stimulation for 2 and 8 h. No changes 
in E-cadherin and vimentin expression were detected. Real-time RT-PCR demonstrated a 
significant increase in SNAI1 and SNAI2 gene expressions in A549 cells (Figure 4.6B), 
grown in the presence of TGF-β1. A decrease in the expression of E-cadherin and 
occludin and a concomitant increase in the expression of vimentin and α-SMA were 
observed by real-time RT-PCR in A549 cells after TGF-β1 stimulation. 
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Figure 4.7 SNAI localization in A549 and mouse AT2 cells. 
Immunofluorescence analysis was performed using a primary 
antibody directed against goat anti-SNAI1 (A) and SNAI2 (B) in 
A549 cells. Localization of SNAI1 (C) and SNAI2 (D) was also 
performed in AT2 cells. Nuclei were visualized by 4’6-diamidino-
2-phenylindole (DAPI) staining. Original maginification is 63×. 
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4.1.7 SNAI1 and SNAI2 protein localization in A549 and primary 
mouse AT2 cells 
 
 
 
 
 
 
 
Since the SNAI transcription factors were regulated at the mRNA level in both 
A549 and in primary mouse AT2 cells, immunofluorescence analysis was performed to 
determine whether their cellular localization was also influenced by TGF-β1 treatment. 
Immunofluorescence analysis revealed increased nuclear localization of endogenous 
  
A B 
C D 
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SNAI1 (A) and SNAI2 (B) upon TGF-β1 treatment for 24 h in A549 cells (Figure 4.7). A 
similar increase in nuclear localization of SNAI1 (C) and SNAI2 (D) was observed in 
AT2 cells (Figure 4.7) after 24 h of TGF-β1 treatment. 
4.2 Analysis of EMT marker expression in an experimental 
model of pulmonary fibrosis 
4.2.1 EMT marker expression in bleomycin-induced pulmonary 
fibrosis 
To analyze whether EMT occurred in a mouse model of bleomycin-induced 
pulmonary fibrosis and to determine whether the expression of SNAI transcription factors 
were regulated during experimental pulmonary fibrosis, mice were subjected to 
bleomycin treatment for 7, 14, or 21 days.  
As depicted in Figure 4.8 (A), in total lung homogenates, semi-quantitative      
RT-PCR revealed decrease in the expression of the epithelial marker E-cadherin as early 
as day 7 after bleomycin treatment compared to controls. At day 7, a concomitant 
increase in the expression of mesenchymal markers vimentin and α-SMA was observed. 
No changes in occludin levels were noted. In total lung homogenates, elevated levels of 
SNAI1 but not SNAI2 were observed 7 days after bleomycin administration. Prominent 
changes in gene expression were evident only at day 7 post bleomycin treatment, 
compared to saline-treated controls. 
Real-time RT-PCR revealed elevated levels of α-SMA 7, 14 and 21 days post 
bleomycin treatment compared to saline-treated controls. A decline in the expression of 
E-cadherin and occludin were not seen. Elevated SNAI1 gene expression in total lung 
homogenates was seen 7, 14 and 21 days after bleomycin administration compared to 
control mice, while an increase in SNAI2 mRNA levels was evident at 14 and 21 days 
after bleomycin treatment. 
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 Figure 4.8 Expression of EMT markers in total lung 
homogenates from bleomycin treated mice. Mice were exposed 
to bleomycin and lungs were harvested after 7, 14, or 21 days, as 
indicated. RNA was isolated from lungs 7, 14 or 21 days after 
bleomycin challenge or saline treatment and semi-qunatitative (A) 
and real-time RT-PCR (B) was performed for EMT marker genes. 
Data are expressed as mean ± SEM, n = 3.
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 Figure 4.9 Expression of EMT markers in AT2 cells from the 
lungs of bleomycin treated mice. EMT marker gene expression 
was quantified by real-time RT-PCR in AT2 cells isolated from 
lungs 7 or 14 days after bleomycin challenge or saline treatment. 
Data are expressed as mean ± SEM; ∗ p<0.05, n = 3. 
 
 
4.2.2 EMT marker expression in AT2 cells of bleomycin-treated 
mice 
To evaluate whether alveolar epithelial cells contributed to EMT in the 
experimental model of lung fibrosis, and to further determine if alveolar epithelial cells 
served as a source of SNAI, AT2 cells isolated from mice treated with bleomycin for 7, 
14, were tested for EMT marker expression. In Figure 4.9, real-time PCR revealed 
significantly elevated levels of both SNAI1 and SNAI2 in AT2 cells isolated from 
bleomycin treated mouse lungs as early as seven days after treatment compared with 
saline treated control. Significantly elevated levels of α-SMA was observed at both day 7 
and 14 after bleomycin treatment, whereas increase in vimentin was seen at day 14. 
Significant repression in E-cadherin and occludin expression was observed in AT2 cells 
at day 7 after bleomycin treatment. 
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 Figure 4.10 Localization of SNAI in mice lungs treated with 
bleomycin. Immunohistochemical analysis of α-SMA, SNAI1, and 
SNAI2 localization was performed in paraffin-embedded lung 
specimen from mice treated with saline or bleomycin for 14 days.  
 
 
4.2.3 SNAI protein localization in lungs of bleomycin treated mice  
Using immunohistochemistry, the localization of α-SMA, SNAI1, and SNAI2 in 
bleomycin-treated lungs was investigated. As depicted in Figure 4.10, α-SMA was 
primarily localized in airway and vascular smooth muscle cells in saline-treated control 
mouse lungs, but was also localized in the lung interstitium after bleomycin treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
While SNAI1 was predominantly localized to perivascular mesenchymal cells and 
alveolar macrophages in saline-treated lungs, it also localized in the lung interstitium, 
particularly in subepithelial areas, after bleomycin treatment. Although little or no 
staining for SNAI2 was detectable in saline-treated mouse lungs, SNAI2 localization was 
detected in the lung interstitium after bleomycin treatment. 
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 Figure 4.11 Expression of EMT markers in IPF. Expression 
analysis of EMT marker genes was performed by real-time RT-PCR 
analysis of total RNA derived from lung biopsies of twelve patients 
with IPF or nine control subjects. Data are expressed as mean ± 
SEM; ∗ p<0.05. 
4.3 Analysis of EMT marker expression in lungs of patients 
with idiopathic pulmonary fibrosis 
4.3.1 Expression of EMT markers in idiopathic pulmonary fibrosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to investigate the occurrence of EMT in IPF, real-time RT-PCR was 
performed and expression profiles of various EMT markers in lung homogenates 
obtained from nine control subjects and twelve IPF lungs (UIP pattern) were compared. 
As depicted in Figure 4.11, real-time RT-PCR revealed significant upregulation of         
α-SMA and vimentin in total lung homogenates from IPF patients compared with control 
subjects. Significant downregulation of occludin in IPF patients compared to control 
subjects was also observed. However an increase in E-cadherin expression in IPF patients 
was detected. 
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 Figure 4.12 Expression of SNAI genes in IPF. Expression 
analysis of EMT marker genes was performed by real-time RT-PCR 
analysis of RNA derived from microdissected alveolar septae from 
lung biopsies of twelve patients with IPF or nine control subjects.
Data are expressed as mean ± SEM; ∗ p<0.05. 
 
To gain additional insight into the possible role of SNAI1 and SNAI2 in EMT 
during IPF, SNAI gene expression was investigated in IPF by comparing mRNA 
expression in lung homogenates obtained from nine control subjects and twelve IPF lungs 
(UIP pattern). Real-time RT-PCR showed significant increased levels of SNAI2 gene 
expression in total lung homogenates from IPF patients compared with control subjects. 
No significant changes were noted in SNAI1 gene expression levels between IPF and 
control subject lung homogenates. 
4.3.2 SNAI gene expression in the lungs of patients with idiopathic 
pulmonary fibrosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To determine if alveolar epithelial cells served as the main source of elevated 
SNAI levels in total lung homogenates of IPF patients, microdissected alveolar epithelial 
cells were obtained from nine control subjects and twelve IPF lungs (UIP pattern). 
Real-time RT-PCR in Figure 4.12, showed elevated levels of SNAI1 and SNAI2 
mRNA in the alveolar septae of IPF patients compared to control subjects, however, only 
expression of SNAI2 was significantly elevated. 
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 Figure 4.13 Expression of SNAI protein in IPF. (A) 
Immunohistochemical analysis of SNAI1 and SNAI2 localization 
was performed on paraffin-embedded lung specimens from IPF 
patients or control subjects. (B) Western blot analysis of SNAI1 and 
SNAI2 was performed with total lung homogenates obtained from
IPF patients and control subjects. Lamin A/C served as the loading 
control.  
 
4.3.3 SNAI protein localization in lungs of patients with idiopathic 
pulmonary fibrosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to analyze the localization pattern of SNAI proteins in IPF, 
immunohistochemistry was performed. As depicted in Figure 4.13, 
immunohistochemistry determined localization of SNAI1 and SNAI2 predominantly in 
A 
 
B 
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alveolar epithelial cells in IPF lungs. In contrast, the control subject lungs showed very 
little or no localization of SNAI1 and SNAI2 in alveolar epithelial cells. Subsequently, 
the expression of SNAI was analyzed at the protein level. Western blot analysis revealed 
elevated protein levels of both SNAI1 and SNAI2 in total lung homogenates obtained 
from six IPF patients compared with six control subjects. Lamin A/C served as a loading 
control. 
4.4 Functional studies in A549 cells 
4.4.1 Effect of ectopically-expressed human SNAI1 on EMT 
marker gene expression in A549 cells 
It has been suggested that SNAI transcription factors mediate the transcriptional 
repression of epithelial markers such as E-cadherin and occludin and thereby triggers 
EMT. To further investigate whether SNAI1 has a functional role in inducing EMT, the 
full-length SNAI1 cDNA was cloned into a mammalian expression vectors and A549 
cells were transiently transfected for 24 and 48 h. 
Next the expression pattern of different epithelial and mesenchymal markers were 
examined. Real-time RT-PCR revealed downregulation of epithelial markers including  
E-cadherin and occludin and upregulation of α-SMA evident 48 h after transfection 
(Figure 4.14A). Similarly upon SNAI1 overexpression, Western blot analysis indicated a 
decrease in the protein expression of E-cadherin and occludin and increase in the protein 
expression of α-SMA compared to empty vector-transfected control (Figure 4.14B).        
α-Tubulin served as a loading control. 
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Figure 4.14 Effect of SNAI1 overexpression on EMT in A549 
cells. EMT marker expression was analyzed by real-time RT-PCR 
(A) and western blot (B) in A549 cells overexpressing human 
SNAI1 protein for 24 and 48 h compared to the empty vector 
control. α-Tubulin served as the loading control. Data are expressed 
as mean ± SEM; ∗ p<0.05, n = 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.2 Effect of ectopically-expressed human SNAI2 on EMT 
marker gene expression in A549 cells 
To further test whether SNAI2 induces EMT and also to determine if SNAI2 has a 
functional role similar to SNAI1 in inducing EMT, the full-length SNAI2 cDNA was 
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Figure 4.15 Effect of SNAI2 overexpression on EMT in A549 
cells. EMT marker expression was analyzed by real-time RT-PCR 
(A) and western blot (B) in A549 cells overexpressing human 
SNAI2 protein for 24 and 48 h compared to the empty vector 
control. α-Tubulin served as the loading control. Data are expressed 
as mean ± SEM; ∗ p<0.05, n = 3. 
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cloned into a mammalian expression vector and A549 cells were transiently transfected 
for 24 and 48 h. The expression patterns of various epithelial and mesenchymal markers 
were then evaluated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Upon SNAI2 overexpression, real-time RT-PCR revealed downregulation of 
epithelial markers including E-cadherin and occludin and upregulation of α-SMA (Figure 
4.15A). Decline in E-cadherin level was significant after 48 h of SNAI2 overexpression. 
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Figure 4.16 siRNA-mediated downregulation of SNAI1 and 
SNAI2 expression in A549 cells. (A, B). The mRNA knockdown 
of four different SNAI1 and SNAI2 siRNA oligonucleotides was 
assayed by semi-quantitative (A) and real-time (B) RT-PCR. In B, 
the relative expression of SNAI1 and SNAI2 was normalized for
PBGD and expressed as log fold change. scr; scrambled siRNA 
oligonucleotide. 
 
Western blot analysis indicated decrease in the protein expression of E-cadherin and 
occludin compared to empty vector control (Figure 4.15B). However, no increase in the 
protein expression of α-SMA was detected. α-Tubulin served as the loading control. 
4.4.3 siRNA-mediated downregulation of SNAI1 and SNAI2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
A 
 
Results  60 
 
Whether a direct causal relationship existed between upregulation of SNAI1 or 
SNAI2 and the process of EMT in A549 cells was next examined. To do so, four 
different sequences of siRNA oligonucleotides targeting SNAI1 and SNAI2 were initially 
characterized (Figure 4.16A and B).  
Quantitative as well as semi-quantitative RT-PCR analysis revealed that three out 
of four SNAI1 and SNAI2 siRNA oligonucleotides were effective in reducing the 
respective mRNA levels in response to TGF-β1 treatment (Figure 4.16A and B). The 
most effective siRNA oligonucleotides targeting SNAI1 and SNAI2 were then used to 
examine the effect of SNAI depletion on EMT.  
4.4.4 Effect of siRNA-mediated downregulation of SNAI1 on 
EMT marker gene expression in A549 cells 
As depicted in Figure 4.17, SNAI1 depletion effectively inhibited TGF-β1-
induced EMT. This was assessed by attenuation of the increase in mesenchymal markers 
as well as the decrease in epithelial markers. Semi-qunatitative RT-PCR (Figure 4.17A) 
showed that in SNAI1-depleted A549 cells treated with TGF-β1, there was an increase in 
mRNA levels of E-cadherin and occludin, with a concomitant decrease in the expression 
of α-SMA compared to the cells transfected with control non-specific scrambled siRNA. 
HSC-70 served as the loading control. These observations were confirmed by real-time 
RT-PCR (Figure 4.17B), which indicated a decline in α-SMA and vimentin, as well as 
increase in E-cadherin, occludin and Tjp1 mRNA levels in SNAI1-depleted A549 cells 
treated with TGF-β1, compared to the control non-specific scrambled siRNA-treated 
cells. 
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Figure 4.17 Effect of siRNA-mediated downregulation of SNAI1 
expression on TGF-β-mediated EMT. Using semi-quantitative 
(A) and real-time (B) RT-PCR analysis, the expression patterns of 
EMT marker genes were assessed in A549 cells after siRNA 
treatment against SNAI1 with or without TGF-β exposures for 24 h.
scr, scrambled siRNA oligonucleotide. Data are expressed as mean 
± SEM; ∗ p<0.05, n = 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.5 Effect of siRNA-mediated downregulation of SNAI2 on 
EMT marker gene expression in A549 cells 
Next, to evaluate whether silencing of SNAI2 attenuated TGF-β1-mediated EMT, 
siRNA-mediated knockdown of SNAI2 was performed in A549 cells. The expression of 
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Figure 4.18 Effect of siRNA-mediated downregulation of SNAI2
expression on TGF-β-mediated EMT. Using semi-quantitative 
(A) and real-time (B) RT-PCR analysis, the expression patterns of 
EMT marker genes were assessed in A549 cells after siRNA 
treatment against SNAI2 with or without TGF-β exposures for 24 h. 
Scr, scrambled siRNA oligonucleotide. Data are expressed as mean 
± SEM; ∗ p<0.05, n = 3. 
 
 
EMT markers was then assessed. Increases in α-SMA and vimentin, as well as a decrease 
in E-cadherin, occludin, and Tjp1 mRNA levels were indicated by both semi-quantitative 
and real-time RT-PCR (Figure 4.18A and B).  
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Figure 4.19 Effect of SNAI1 and SNAI2 on TGF-β-induced cell 
migration. siRNA-treated A549 cells where treated with or without 
TGF-β1 for 24 h and the relative migration potential of A549 cells 
was assessed. scr, scrambled siRNA oligonucleotide Data are 
expressed as mean ± SEM; ∗ p < 0.05, n = 3. 
 
4.4.6 Role of SNAI1 and SNAI2 in TGF-β1-induced cell migration 
One of the consequences of transition from an epithelial to a mesenchymal 
phenotype is the acquisition of migratory properties. Thus, the migratory potential of 
A549 cells was measured by performing an in vitro migration assay. Twenty four hours 
of TGF-β1 treatment to cells transfected with non-specific siRNA, led to a four-fold 
induction of cell migration (Figure 4.19). Silencing of SNAI1 and SNAI2 by siRNA 
significantly reduced TGF-β1-induced migration in these cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.5 Analysis of EMT in unilateral ureteral obstruction 
model of renal fibrosis 
4.5.1 EMT marker expression in a unilateral ureteral model of 
renal fibrosis 
Sperandio et al., investigated the role of inflammatory leukocytes in EMT in 
neonatal obstructive nephropathy (B. Lange-Sperandio, et al., 2007). The authors 
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Figure 4.20 Effect of BX471 on UUO-induced EMT marker 
expression. Neonatal mice were subjected to unilateral ureteral 
obstruction (UUO) or sham operation and treated with BX471 or 
vehicle, as indicated. Whole kidney extracts were prepared, total 
RNA isolated, and RT-PCR for the indicated genes performed. 
RNA profiles were obtained in cohorts that were harvested at days 1 
(A), 5 (B) and 14 (C) after UUO or sham operation, respectively. 
 
demonstrated that UUO in neonatal mice enhanced leukocyte infiltration, tubular 
apoptosis and caused EMT in renal fibrosis. Furthermore, they also reported that 
treatment with BX471, a leukocyte receptor inhibitor, reduced leukocyte infiltration into 
the obstructed kidney, inhibited tubular apoptosis, atrophy and also decreased interstitial 
collagen deposition. In collaboration with Sperandio et al., the following experiment was 
performed: to examine whether EMT occurs in UUO model of renal fibrosis in neonatal 
mice, EMT markers were assessed, including SNAI transcription factors. To further 
investigate whether leukocyte recruitment regulated EMT, neonatal mice with UUO were 
treated with leukocyte receptor blocker BX471.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
C
B 
Results  65 
 
As depicted in Figure 4.20, SNAI1 and SNAI2 expression levels were rapidly 
increased in obstructed kidneys, as early as day 1 after UUO, compared with sham-
treated control. In the presence of BX471, this increase in SNAI1 and SNAI2 mRNA was 
completely attenuated. Increased expression of α-SMA and vimentin became evident at 
day 5 and at day 14 after UUO. Expression of both these mesenchymal markers was 
attenuated upon BX471 treatment. SNAI1 and SNAI2 expression preceded the induction 
of α-SMA and vimentin. Total E-cadherin mRNA abundance in the kidney remained 
unchanged by BX471 treatment and UUO surgery. 
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5 Discussion 
5.1 Assessment of EMT in alveolar epithelial cells 
5.1.1 TGF-β1 as a potent inducer of EMT  
In many organs such as the kidney, liver, and skin, TGF-β1 has been identified as 
a major inducer of EMT (E.P. Bottinger, et al., 2002, J. Zavadil, et al., 2007, M. Zeisberg, 
et al., 2007). TGF-β1-driven EMT in AECs is currently the subject of intense research. 
Initially, the ability of TGF-β1 to promote EMT in AECs was reported in vitro, in 
primary AT2 cell from SD rats (H.W. Yao, et al., 2004). Subsequently, a growing number 
of studies have demonstrated the occurrence of EMT in TGF-β1-treated AECs from both 
human and rat origins (H. Kasai, et al., 2005, B.C. Willis, et al., 2005). To date, very little 
is known concerning the molecular mediators involved in EMT in the lungs. Elucidation 
of the molecular mediators as well as the underlying mechanism that regulate EMT both 
in vitro and in vivo in lungs, is an active area of research. 
At the onset of this study, the highest possible purity of freshly-isolated primary 
mouse AT2 cells could be demonstrated. These cells were responsive to TGF-β1 as they 
expressed all necessary TGF-β signaling components. Upon exposure to TGF-β1, AT2 
cells demonstrated an increase in the expression of mesenchymal markers (α-SMA) with 
a corresponding decrease in epithelial markers (E-cadherin, and Tjp1), suggestive of 
EMT. The occurrence of EMT was ultimately reinforced by the presence of α-SMA and 
Tjp1 double-positive cells in TGF-β1-treated, but not in untreated cells. Upon TGF-β1 
exposure, the expression of epithelial markers was repressed, conversely the expression 
of mesenchymal markers was induced in AT2 cells. These results in AT2 cells was 
confirmed in alveolar epithelial A549 cell line, free of fibroblast contamination. Data 
from the current study indicates that AECs undergo EMT. These findings are in 
agreement with recent studies reported in A549 cells and primary murine AT2 cells, 
highlighting the role of TGF-β-mediated EMT in alveolar epithelial cells (S. Ando, et al., 
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2007, H. Kasai, et al., 2005, J.H. Kim, et al., 2007, K.K. Kim, et al., 2006, B.C. Willis, et 
al., 2005, H.W. Yao, et al., 2004). Another study previously described that 5 ng/ml of 
TGF-β1 induced EMT at late time point, 72 h, in primary mouse AT2 cells (S. Ando, et 
al., 2007). In addition to these previous reports, the current study demonstrates that a low 
dose of TGF-β1 (2 ng/ml) was sufficient to induce EMT in A549 and primary mouse 
AT2 cells, and that EMT is an early phenomenon, observed as early as 24 h at the protein 
level and 2 h at the RNA level, after TGF-β1 stimulation. Real-time RT-PCR illustrated a 
decline in E-cadherin and an increase in α-SMA levels in A549 and AT2 cells, 
respectively. However, these changes were not detectable by semi-quantitative RT-PCR. 
A possible explanation for this discrepancy in data may be that semi-quantitative RT-
PCR is not as sensitive as real-time RT-PCR in detection of gene expression. Recently, 
TGF-β1-induced EMT has also been demonstrated in triple transgenic mouse model in 
vivo in AECs (K.K. Kim, et al., 2006). Kasai et al., identified that TGF-β1 mediates EMT 
via Smad2-dependent pathways in A549 cells (H. Kasai, et al., 2005). Further studies will 
be required to define the mechanism of EMT in AECs. 
5.1.2 Implication of SNAI in EMT of alveolar epithelial cells 
EMT is a complex process involving restructuring the cell cytoskeleton, cell 
membrane, and cell-cell junction (E.D. Hay, et al., 1995). Previous studies have 
implicated several regulatory molecules in EMT (M.A. Huber, et al., 2005, J.P. Thiery, et 
al., 2006). In the present study, a comparison of the gene expression profile of EMT 
markers in mouse primary AT2 and human A549 cells revealed that TGF-β1 triggered an 
immediate transcriptional activation of the zinc finger transcription factors SNAI1 and 
SNAI2 in both cells. TGF-β1 treatment also increased nuclear localization of the zinc 
finger transcription factors in both cell types.  
5.1.2.1 Processes regulating SNAI nuclear localization 
The distribution of SNAI1 and SNAI2 are not homogeneous in the nucleus. This 
is in accordance with previous studies demonstrating the presence of SNAI1 and SNAI2 
in discrete foci in the nucleus (D. Dominguez, et al., 2003, K. Hemavathy, et al., 2000). 
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Nuclear speckles have been identified as sites of active RNA splicing on the basis of their 
costaining with factor U2AF65 (D. Dominguez, et al., 2003). SNAI1 nuclear 
translocation is aided by the presence of nuclear export signal. SNAI2 lacks this NES. 
The SLUG domain, whose function has yet to be identified and may regulate its nuclear 
translocation. 
A recent study suggests that SNAI1 function may be regulated by its intracellular 
location, as serine phosphorylation-dependent cytoplasmic redistribution of SNAI1 
inhibits its activity as a transcriptional repressor (D. Dominguez, et al., 2003). Another 
study showed that GSK-3β phosphorylation of SNAI1, promotes its degradation and may 
be another mode of SNAI1 regulation (B.P. Zhou, et al., 2004). SNAI1 is regulated by 
GSK-3β, which results in either destruction or subcellular localization, depending on 
which of the two phosphorylation motifs within SNAI1 is targeted. Pak1 phosphorylation 
also promotes SNAI1’s nuclear accumulation and consequently its repressor activity in 
the nucleus (Z. Yang, et al., 2005). In zebrafish embryos, nuclear localization of SNAI1 
is mediated by zinc tranporter LIV1 (S. Yamashita, et al., 2004). The stability of SNAI1 
is not only controlled by its phosphorylation state but also by its oxidative state, as 
demonstrated by interaction with LOXL2 and LOXL3 (H. Peinado, et al., 2005). To date, 
less is known about post-translational regulation of SNAI2. Recently, in Xenopus, partner 
of paired (Ppa) protein has shown to regulate SNAI2 stability and degradation (A.E. 
Vernon, et al., 2006). Further investigations of SNAI regulation may provide a novel 
approach for disease prevention and treatment. 
5.1.2.2 SNAI transcription factors in TGF-β1-induced EMT 
A direct effect of TGF-β1 signaling on the induction of SNAI1 and SNAI2 was 
recently demonstrated in MDCKII and MDCK cells, which are canine renal epithelial cell 
lines (T. Morita, et al., 2007, H. Peinado, et al., 2003). These studies reported that TGF-
β1 directly induced SNAI1 or SNAI2 expression by interacting with TGF-β1 response 
elements located in SNAI promoters. This is in line with the observed elevated 
expression levels of SNAI upon TGF-β1 stimulation in the current study. Furthermore, 
SNAI1 and SNAI2 are known to play an important role in the disassembly of cell-cell 
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junctions namely, adherens junctions, tight junctions and desmosomes, and separation of 
cells induced by TGF-β. In accordance with the present study, elevated levels of SNAI1 
were also demonstrated at the RNA level in A549 cells treated with TGF-β1 (J.H. Kim, et 
al., 2007).  
5.2 Evidence of EMT in bleomycin mouse model of 
pulmonary fibrosis 
Bleomycin induces peribrochial fibrosis in the mouse, and this recapitulates 
histological features of human IPF. This disease model has been widely-used as a tool for 
the study of the pathogenetic mechanisms of IPF. The current study demonstrates the 
occurrence of EMT in this animal model, with AT2 cells being the key contributors of 
EMT. Monitoring the expression profile of EMT markers in total lung homogenates by 
semi-quantitative RT-PCR indicates the occurrence of EMT as early as day 7 post 
bleomycin administration. However, semi-quantiative RT-PCR failed to detect the 
elevated levels of mesenchymal markers at days 14 and 21 after bleomycin treatment as 
observed by real-time RT-PCR. Furthermore, increases in mesenchymal marker were not 
significant by real-time RT-PCR, and no repression of epithelial markers was observed 
after bleomycin treatment. Thus, the occurrence of EMT in total lung homongenates of 
bleomycin-treated mice was not conclusive.  
A recent study was unable to detect evidence of EMT by immunohistochemistry 
in four week and twelve day bleomycin-treated rat and mouse lungs, respectively (K. 
Barth, et al., 2005). This is consistent with another study, where the authors were also 
unable to detect EMT by dual-immunohistochemistry in bleomycin-treated mouse lungs 
(M. Yamada, et al., 2008). These studies suggest that EMT may be a transient 
phenomenon. Furthermore, the possibility that cells undergoing EMT are rarely found in 
this animal model cannot be excluded. 
However, Wu Z et al., demonstrated that a small subset of bronchiolar and 
alveolar epithelial cells could convert into myofibroblasts in vivo, using an α-SMA-Cre 
transgenic mouse treated with bleomycin (Z. Wu, et al., 2007). In agreement with this 
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report, in the present study, isolated AT2 cells were more promising that total lung 
homogenates from animals treated with bleomycin and provided clear evidence for the 
occurrence of EMT in the experimental model of lung fibrosis. 
5.2.1 Implication of SNAI in bleomycin-induced lung fibrosis 
Significant changes in SNAI gene expression were observed in the bleomycin 
model, thereby confirming the importance of these transcription factors in this disease 
model in vivo, as evident in vitro, in AECs. In total mouse lung homogenates, elevated 
levels of both SNAI1 and SNAI2 were demonstrated after bleomycin treatment. 
Significant elevation in SNAI1 and SNAI2 levels in AT2 cells isolated from bleomycin 
treated lungs, as early as day 7, as well as increased localization of these key transcription 
factors in bleomycin treated lung sections implicate SNAI1 and SNAI2 in EMT in this 
experimental model of fibrosis, early in the disease process. 
5.3 Assessment of EMT marker expression in idiopathic 
pulmonary fibrosis 
IPF is the most common form of idiopathic interstitial pneumonias, which exhibits 
a distortion of normal tissue architecture and a loss of lung function. IPF exhibits a poor 
prognosis and unresponsiveness to currently available therapies, reflecting our limited 
understanding of the basic mechanisms and mediators implicated in the pathogenesis of 
this progressive and fatal fibrotic disease (W.D. Travis and T.E. King, Jr, 2002, T.J. 
Gross, et al., 2001). The typical histological appearance of IPF is called UIP and includes 
the heterogeneous transformation of normal lung tissue by coexisting emphysematous 
and fibrotic lesions, as evident by honeycomb cysts and fibroblast foci (A.L. Katzenstein, 
et al., 1998). These processes lead to an increase in total lung collagen levels with the 
inability of the lung to properly facilitate gas exchange.  
The hallmark lesions of IPF are the fibroblast foci, which are aggregates of 
activated myofibroblasts promoting excessive ECM deposition. The presence of 
fibroblast foci is an important prognostic factor and their number has been shown to 
correlate with survival in IPF (T.E. King, Jr., et al., 2001). Fibroblast foci consistently 
Discussion  71 
 
occur in the subepithelial layer between areas of collagen deposition and normal alveoli, 
close to areas demonstrating alveolar epithelial cell injury and repair. In lungs of patients 
with IPF, these activated myofibroblasts are thought to represent the key cell-type 
responsible for the enhanced secretion and deposition of ECM. While historically, 
inflammatory processes were thought to trigger and facilitate the progression of IPF (T.J. 
Gross, et al., 2001). This monocausal view has recently been questioned, primarily due to 
the ineffectiveness of anti-inflammatory therapy in IPF (F. Chua, et al., 2005, J. Gauldie, 
et al., 2002, M. Selman, et al., 2001). Key pathophysiological events in IPF that are 
currently discussed include local growth factor-dependent fibroproliferation, repetitive 
alveolar epithelial cell injury with subsequent EMT and fibroblast activation, and trans-
differentiation of circulating precursor cells into myofibroblasts, which migrate to the 
diseased lung (B. Hinz, et al., 2007, B.C. Willis, et al., 2006). 
A key question in IPF pathogenesis that remains to be answered is: what is the 
origin of the activated myofibroblast? Due to the spatio-temporal heterogeneity of IPF, 
many studies have focused on the analysis of local profibrotic growth factor/cytokine 
release in the lung, in an attempt to elucidate regulatory factors able to generate activated 
cell types. In this respect, TGF-β1 has emerged as one of the key profibrotic growth 
factors in the lung (G.C. Blobe, et al., 2000).  
In this current study, significantly elevated levels of α-SMA and vimentin and a 
concomitant decline in occludin mRNA levels in total lung homogenates from IPF 
patients compared with control subjects, suggests the occurrence of EMT in IPF. In 
agreement with this observation, a recent report by B.C.Willis et al., demonstrated the 
colocalization of α-SMA and pro-SP-B or TTF-1 in AECs of IPF patient lung sections 
(B.C. Willis, et al., 2005). A study by K.K.Kim et al., revealed costaining of pro-SPC and 
N-cadherin in cells near sites of alveolar collapse and AEC clustering in lung biopsies 
from IPF patients (K.K. Kim, et al., 2006). These studies provide evidence of EMT in 
lung tissue biopsies, raising the possibility that this process may contribute to the 
increased pool of myofibroblasts in lung fibrosis. However, a more recent study failed to 
identify EMT in pulmonary fibrosis by dual-immunohistochemistry (M. Yamada, et al., 
2008). Possible explanations for this apparently discordant observation are that EMT is a 
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very transient process and it is a possibility that epithelial cells in transition may rapidly 
lose expression of epithelial markers below the level of detection before mesenchymal 
markers expression is above the level of detection. Thus, the incidence of cells              
co-expressing epithelial and mesenchymal markers may be underestimated by double 
immunohistochemistry (M. Yamada, et al., 2008). 
Loss of E-cadherin expression is a primal molecular event that contributes to 
tumor invasion and metastasis (E.M. Fish, et al., 1994). In contrast to the anticipated 
decrease in expression levels of E-cadherin in IPF patients compared to control subjects, 
an elevated expression of E-cadherin in IPF patient lung homongenates was observed. A 
possible explanation is that E-cadherin may be a very robust epithelial cell marker and 
fibroblast retain the expression of this marker. It will be of interest to examine E-cadherin 
expression in microdissected alveolar septae from IPF patients. 
Does EMT constitute a relevant mechanism for the observed increase in activated 
myofibroblasts in IPF and other forms of lung fibrosis? This is an essential question of 
therapeutic relevance, and this study suggests that SNAI-mediated EMT indeed 
represents an early event of pathophysiological relevance.  
5.3.1 Implication of SNAI in idiopathic pulmonary fibrosis 
Previously, it has been shown that SNAI1-deficient mice die at the gastrulation 
stage (E.A. Carver, et al., 2001), because of the inability to undergo EMT, reinforcing the 
importance of the SNAI transcription factors in the process of embryonic development. 
While the importance of SNAI-mediated EMT has been unequivocally demonstrated in 
embryonic development and organogenesis, its importance in pathophysiological 
conditions such as cancer and tissue fibrosis are less well substantiated and require 
further investigation. In cancer, SNAI family members have been shown to facilitate the 
delamination of cells from the primary tumor and their metastatic potential (H. Peinado, 
et al., 2007). Extensive analyses of tumor cell lines and biopsies obtained from primary 
tumors from the breast, colon, liver, and stomach have confirmed that SNAI plays a 
pivotal role in progression of cancer (V. Dasari, et al., 2006). Recently, high SNAI 
expression has been associated with poor prognosis and tumor recurrence in lung cancer 
Discussion  73 
 
patients (M.L. Lee, et al., 2005, N.K. Kurrey, et al., 2005, T.A. Martin, et al., 2005, J.Y. 
Shih, et al., 2005). Increasing evidence supports the idea that the in vivo action of 
different SNAI family members in epithelial marker repression can be modulated by their 
relative concentrations, as well as by specific cellular or tumoral contexts (T.A. Martin, et 
al., 2005). In tissue fibrosis, SNAI-mediated EMT is suggested to play an important role, 
wherein SNAI1 is activated in epithelial cells that undergo EMT in renal fibrosis (M. 
Sato, et al., 2003) and lens cataract formation (S. Saika, et al., 2004), whereas SNAI2 is 
activated during skin wound healing (P. Savagner, et al., 2005).  
However, in vivo evidence in lung fibrosis remains modest. The present study, 
points out a crucial role for SNAI transcription factors in the development of IPF, as 
elevated levels of SNAI2 were detected both at the RNA and protein levels in total lung 
homogenates and microdissected alveolar septae from IPF patients compared to control 
subjects. Elevated protein levels of SNAI1 in homogenates of lung from patients with IPF 
was also observed, whereas no significant changes were detected at RNA level. However, 
increased protein expression of both SNAI1 and SNAI2 were detected in the IPF patient 
lungs compared to control donor lungs. It remains to be seen if these SNAI transcription 
factors play a specific or redundant role in EMT during IPF. 
5.4 Analysis of SNAI mediated transcriptional control of 
EMT in alveolar epithelial cells 
By applying both loss-of-function and gain-of-function approaches, the role of 
these transcription factors in EMT from perspective of carcinogenesis and development, 
have been extensively examined (E. Batlle, et al., 2000, A. Cano, et al., 2000). However, 
to date, the role of these transcription factors in AECs is not known and the current study 
offers new insight into the functional role of SNAI in EMT in AECs. 
The data presented here are consistent with the notion that SNAI1 and SNAI2 are 
essential mediators involved in the initiation and perpetuation of TGF-β1-mediated EMT 
in the lung. Since EMT could be inhibited in cell culture with siRNA targeting the two 
key transcription factors SNAI1 and SNAI2, it will have to be demonstrated whether in 
vivo interference with these factors may lead to an attenuation of fibrosis. The current 
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study offers evidence that SNAI1 and SNAI2 endow cells with capacity to migrate. 
Previously, our group has determined that TGF-β induces migration in AECs (H. Yu, et 
al., 2008). Recently, SNAI1 RNAi based loss of function studies in A549 cells showed 
SNAI1 increases chemoresistance of cancer cells to anti-cancer agents (W. Zhuo, et al., 
2008). This study did not examine the effect of SNAI silencing on EMT markers. The 
current study also presents evidence that SNAI1 and SNAI2 induces EMT even in the 
absence of TGF-β1, hence recapitulating their role as potent inducers of EMT. In 
accordance to these observations, SNAI1 and SNAI2 have previously been implicated in 
a central role in the process of EMT in both developmental, as well as in tumoral context 
in various cultured epithelial cells. In the present study, ectopically-expressed SNAI1 
induces complete EMT, whereas, SNAI2 overexpression induces partial EMT by 
repression of E-cadherin and Occludin expression and no induction in α-SMA expression. 
This data suggest that SNAI family members may use different mechanisms to induce 
EMT, and also suggest the existence of functional differences between SNAI1 and 
SNAI2 as previously described (H. Peinado, et al., 2005). Further functional analyses in 
vivo may yield diagnostic markers as well as therapeutic approaches. 
5.5 EMT in a unilateral ureteral obstruction model of renal 
fibrosis 
Tubulo-interstitial fibrosis is a constant feature of chronic renal failure and it is 
suspected to contribute to the deterioration of renal function. Renal fibrosis is also 
characterized by exaggerated accumulation and replication of fibroblasts. EMT as a key 
contributor of myofibroblasts has been well document in kidney fibrosis (R. Kalluri, et 
al., 2003). Further, using the classical UUO mouse model of renal fibrosis, Iwano et al., 
demonstrated that the epithelial cells contribute 36% to EMT (M. Iwano, et al., 2002). 
The current focus is to identify new therapeutics in reversing EMT and thereby 
attenuating kidney fibrosis. Using the UUO model, another group has also demonstrated 
reverse MET, the reverse process of EMT by treatment with BMP-7 (M. Zeisberg, et al., 
2005). 
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5.5.1 SNAI transcription factors in unilateral ureteral obstruction 
model of renal fibrosis 
Role of SNAI transcription factors have been demonstrated in the kidney. In the 
current collaborative study, both SNAI1 and SNAI2, key regulators of EMT, rapidly 
increases in neonatal UUO. These data suggest a close relationship between the degree of 
leukocyte infiltration and EMT, due to the attenuation in levels of SNAI1 and SNAI2 
after leuckocyte receptor blocker, (BX471) treatment. Furthermore, detection of high 
SNAI levels as early as day 1 after UUO indicates that SNAI1 and SNAI2 are early 
markers of EMT. While elevated levels of mesenchymal markers were evident on day 5 
and day 14 after UUO, no changes in the expression of the epithelial marker, E-cadherin 
were detected at any stage investigated after UUO. However, using immunofluorescence, 
E-cadherin expression was observed in the intercellular junction area of renal tubules. 
After UUO, E-cadherin expression strongly decreased in the obstructed kidney over time. 
Furthermore, treatment with BX471 reduced the loss of E-cadherin in UUO kidneys. The 
data presented here suggest that EMT occurs in neonatal UUO mice and infiltrating 
leukocytes induce EMT in neonatal model of renal fibrosis. This study argues for a 
significant role of infiltrating leukocytes in the induction of EMT and the progression of 
interstitial fibrosis in congenital obstructive nephropathy. 
5.6 Conclusions and future perspectives 
The key finding of the present study is that TGF-β1 is a potent inducer of EMT in 
primary mouse alveolar epithelial type II cells and in the human alveolar epithelial A549 
cell line. Transcription factors of the SNAI family are key regulators of TGF-β1-induced- 
EMT, and depletion of SNAI1 and SNAI2 by siRNA technology inhibited EMT in 
response to TGF-β1. Further, silencing of SNAI transcription factors abrogates the   
TGF-β1-induced migratory potential of A549 cells. Ectopic expression of SNAI 
promotes EMT even in the absence of TGF-β1. Elevated expression of SNAI1 and 
SNAI2 were initially observed in vitro and later substantiated in vivo, in the bleomycin 
model of pulmonary fibrosis, early in disease. An increase of SNAI transcription factors 
Discussion  76 
 
was also corroborated in IPF patient lungs compared to control lungs. In sum, this study 
presents clear in vitro and in vivo evidence demonstrating that EMT occurs in primary 
AT2 cells in response to a major profibrogenic cytokine, TGF-β1. It may be speculated 
that EMT is an early event in tissue fibrosis such as IPF and that activation and nuclear 
localization of SNAI transcription factors constitutes an important aspect in EMT of 
alveolar epithelial cells and thus, these findings may be of significance to the field. 
Furthermore, the detection of SNAI transcription factors early in EMT in a UUO model 
of renal fibrosis and the inhibition of EMT by leukocyte blocker treatment further 
emphasizes the significance of SNAI transcription factors in EMT as a causal factor in 
disease mechanism and also as a potential target to provide either preventive or 
therapeutic efficacy. This pathway has implications for several active fields of research 
and may be considered as a potential target of therapeutic interventions.  
In the future, using a microarray approach, novel EMT markers in AECs have to 
be screened. Furthermore, to identify mode of SNAI regulation, a comprehensive 
investigation of downstream targets and interaction partners of these zinc finger proteins 
is required. Few post-translational modifications have been reported to regulate SNAI 
factors and a comprehensive study on SNAI post-translational modifications is an avenue 
that deserves further examination. The screening and identification of other SNAI family 
members as causal factors in EMT in lung fibrosis is of immense interest. It is of 
particular interest to clarify whether SNAI transcription factors are involved in EMT in 
other animal models of pulmonary fibrosis and also to detect whether lung fibrosis can be 
induced in conditional SNAI mouse knockout models. It is also essential to elucidate 
whether TGF-β1 activates SNAI in a Smad-dependent or independent manner. In the near 
future, it will be imperative to determine whether EMT can be reversed and if so, 
identification of molecules inhibiting or modulating the SNAI transcription factors may 
prove to be potentially beneficial in the treatment of IPF. 
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6 Appendix 
Table 6.1 Human RT-PCR primers 
 
 
Gene Bank 
Accession 
Number 
  
Forward primer (5´- 3´) Reverse primer (5´- 3´) 
Annealing 
Temp. 
(°C) 
Cycle 
Number 
Amplicon  
Size (bp) 
SNAI1 
NM_005985 
TTTACCTTCCAGCAG 
CCCTA 
TGACATCTGAGTGGG 
TCTGG 55 28 616  
SNAI2 
NM_003068 
CCATGCCTGTCATAC 
CACAA 
TTGGAGCAGTTTTTG 
CACTG 55 28 631 
α-SMA 
NM_001613 
AGTTATGGTGGGTAT 
GGGTCAGAA 
GAGGGAAGGTGGTTT 
GGGAGA 62 30 1000 
vimentin 
NM_003380 
CGAAAACACCTGCA 
ATCTT 
TCCAGCAGCTTCCTG 
TAGGT 55 28 693 
E-cadherin 
NM_004351 
GGTTCAAGCTGCTGA 
CCTTC 
CTCAAAATCCTCCCT 
GTCCA 55 28 631 
occludin 
NM_002538 
TATGGAGGAAGTGGC 
TTTGG 
TCATTCACTTTGCCA 
TTGGA 62 30 683 
HSC-70 
NM_006597 
TTACCCGTCCCCGATT 
TGAAGAAC 
TGTGTCTGCTTGGTA 
GGAATGGTGGTA 55 22 330 
 
Table 6.2 Mouse RT-PCR primers 
 
 
Gene Bank 
Accession 
Number 
  
Forward primer (5´- 3´) Reverse primer (5´- 3´) 
Annealing 
Temp. 
(°C) 
Cycle 
Number 
Amplicon  
Size (bp) 
Smad2 
NM_010754 
CTCCGGCTGAACTGT 
CTCCTACT 
TTACAGCCTGGTGGG 
ATCTTACA 60 25 409 
Smad3 
NM_016769 
AGAACGGGCAGGAG 
GAGAAGTGGT 
GGATTCGGGGAGAGG 
TTTGGAGA 60 25 565 
Smad4 
NM_008540 
ACAGAGAACATTGGA 
TGGAC 
AGTAGCTGGCTGAGC 
AGTAA 55 28 500 
Smad6 
NM_008542 
GAGCACCCCCATCTT 
CGTCAA 
AACAGGGGCAGGAGG 
TGATG 60 25 234 
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Smad7 
NM_001042660 
CCTCCTCCTTACTCC 
AGATA 
ACGCACCAGTGTGAC 
CGATC 60 28 166 
ALK1 
NM_009612 
AGGGCCGATATGGTG 
AGGTGTGG 
GCCGGTTAGGGATGG 
TGGGTGTC 58 24 735 
ALK5 
NM_009370 
AGAGCGTTCATGGTT 
CCGAGAG 
GGGGCCATGTACCTT 
TTAGTGC 59 25 
429 
TβRII 
NM_031132 
GAGAGGGCGAGGGCG 
AGGAGTAAAGG 
GTGGTAGGTGAGCTT 
GGGGT 60 24 
410/500 
SNAI1 
NM_011427 
CACCCTCATCTGGGA 
CTCTC 
GCCAGACTCTTGGTG 
CTTGT 58 30 
604 
SNAI2 
NM_011415 
AACATTTCAACGCCT 
CCAAG 
CAGTGAGGGCAAGAG 
AAAGG 58 32 
631 
α-SMA 
NM_007392 
CTGACAGAGGCACCA 
CTGAA 
CTTCTGCATCCTGTC 
AGCAA 60 25 
490 
vimentin 
NM_0117013 
CGCAGCCTCTATTCC 
TCATC 
AGCCACGCTTTCATA 
CTGCT 58 30 
693 
E-cadherin 
NM_009864 
AGTTTACCCAGCCGG 
TCTTT 
AGGGTTCCTCGTTCT 
CCACT 58 30 
602 
occludin 
NM_008756 
GCTCTCTCAGCCAGC 
GTACT 
AATCATGAACCCCAG 
GACAA 58 30 
640 
GAPDH 
NM_008084 
ACACATTGGGGGTAG 
GAACA 
A 
AACTTTGGCATTGGA 
AGG 60 21 
225 
PBGD 
NM_001110251 
GGTACAAGGCTTTCA 
CGATCGC 
ATGTCCGGTAACGGC 
GGC 58 23 
150 
 
Table 6.3 Human real-time RT-PCR primers 
 
 
Gene Bank 
Accession Number 
  
Forward primer (5´- 3´) Reverse primer (5´- 3´) 
SNAI1 
NM_005985 
TGGGCGCTCCGTAAA 
CAC 
ACGAGGGAAACGCAC 
ATCA 
SNAI2 
NM_003068 
GGCAAGGCGTTTTCC 
AGAC 
CTCTGTTGCAGTGAG 
GGCAA 
α-SMA 
NM_001613 
CGAGATCTCACTGAC 
TACCTCATGA 
AGAGCTACATAACAC 
AGTTTCTCCTTGA 
vimentin 
NM_003380 
GAGAACTTTGCCGTT 
GAAGC 
TCCAGCAGCTTCCTG 
TAGGT 
E-cadherin 
NM_004351 
ATACACTCTCTTCTC 
TCACGCTGTGT 
ATACACTCTCTTCTC 
TCACGCTGTGT 
occludin 
NM_002538 
GCCGAGGAGCCGGTC 
TAG 
CAGGATGAGCAATGC 
CCTTT 
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Tjp1 
NM_003257 
GAGGAAACAGCTATA 
TGGGAACAAC 
TGACGTTTCCCCACT 
CTGAAA 
PBGD 
NM_000190 
CCCACGCGAATCACT 
CTCAT 
 
TGTCTGGTAACGGCA 
ATGCG 
 
 
Table 6.4 Mouse real-time RT-PCR primers 
 
 
Gene Bank 
Accession Number 
  
Forward primer (5´- 3´) Reverse primer (5´- 3´) 
SNAI1 
NM_011427 
AGCCCAACTATAGCG 
AGCTG 
GGGGTACCAGGAGAG 
AGTCC 
SNAI2 
NM_011415 
GAAGCCCAACTACAG 
CGAAC 
AGGAGAGTGGAGTGG 
AGCTG 
α-SMA 
NM_007392 
GCTGGTGATGATGCT 
CCCA 
GCCCATTCCAACCAT 
TACTCC 
vimentin 
NM_0117013 
TGAAGGAAGAGATGG 
CTCGT 
TCCAGCAGCTTCCTG 
TAGGT 
E-cadherin 
NM_009864 
CCATCCTCGGAATCC 
TTGG 
TTTGACCACCGTTCT 
CCTCC 
occludin 
NM_008756 
CCGCCAAGGTTCGCT 
TATC 
TCAGGTCTGTAAGGA 
GGTGGACTT 
Tjp1 
NM_009386 
ACTATGACCATCGCC 
TACGG 
GGGGATGCTGATTCT 
CAAAA 
PBGD 
NM_001110251 
GGTACAAGGCTTTCA 
CGATCGC 
ATGTCCGGTAACGGC 
GGC 
 
Table 6.5 Human siRNA sequences 
 
 
Gene name 
 
Sense Sequence 
 
Antisense Sequence 
SNAI1-si#1 ACUCAGAUGUCAAGAAGUAUU PUACUUCUUGACAUCUGAGUUU 
SNAI1-si#2 GCAAAUACUGCAACAAGGAUU PUCCUUGUUGCAGUAUUUGCUU 
SNAI1-si#3 GCUCGGACCUUCUCCCGAAUU PUUCGGGAGAAGGUCCGAGCUU 
SNAI1-si#4 GCUUGGGCCAAGUGCCCAAUU PUUGGGCACUUGGCCCAAGCUU 
SNAI2-si#1 GGACACACAUACAGUGAUUUU 
 
PAAUCACUGUAUGUGUGUCCUU 
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SNAI2-si#2 UAAAUACUGUGACAAGGAAUU PUUCCUUGUCACAGUAUUUAUU 
SNAI2-si#3 GAAUGUCUCUCCUGCACAAUU 
 
PUUGUGCAGGAGAGACAUUCUU 
SNAI2-si#4 GAAUCUGGCUGCUGUGUAGUU PCUACACAGCAGCCAGAUUCUU 
 
 
Table 6.6 Primary antibodies used for western blotting (WB), 
immunohistochemistry (IHC) and immunofluorescence (IF) 
 
Dilution 
Primary Host 
WB IHC IF 
Company  Catalog number 
SNAI1 Rat 1:50 1:20  
K.F. Becker, et 
al., 2006 
Technical 
University of 
Munich 
SNAI1 Rabbit 1:100  1:100 Santa Cruz sc-28199 
SNAI2 Mouse 1:300   Cell Signaling L40C6 
SNAI2 Goat  1:100 1:100 Santa Cruz sc-10437 
α-SMA Mouse 1:300 1:500 1:500 Sigma-Aldrich A5228 
E-cadherin Mouse 1:500  1:300 BD Biosciences 610181 
occludin Rabbit 1:1000  1:100 Zymed 40-4700 
Tjp1 Rabbit   1:100 Zymed 61-7300 
proSP-C Rabbit   1:100 Chemicon AB3786 
lamin A/C Mouse 1:5000   Santa Cruz sc-20681 
α-tubulin Mouse 1:5000   Santa Cruz sc-5286 
 
Table 6.7 Secondary antibodies used for western blotting, immunohistochemistry 
and immunofluorescence  
 
Secondary Host Dilution Company Catalog number 
Western blotting 
HRP-conjugated  
anti-mouse IgG 
Rabbit 1:3000 Pierce 31450 
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HRP-conjugated  
anti-rabbit IgG 
Goat 1:3000 Pierce 31460 
HRP-conjugated  
anti-rat IgG 
Rabbit 1:3000 Pierce 31420 
Immunofluorescence 
FITC-conjugate  
anti-goat IgG 
Rabbit 1:300 Zymed 811611 
FITC-conjugate  
anti-mouse IgG 
Goat 1:300 Zymed 816511 
FITC-conjugate 
anti-rabbit IgG 
Goat 1:300 Zymed 816111 
Alexa Fluor 546 
anti-mouse IgG 
Goat 1:300 Invitrogen A11030 
Immunohistochemistry 
Biotinylated  
anti-mouse IgG 
 Ready to 
use 
Invitrogen 956543B 
Biotinylated  
anti-goat IgG 
 Ready to 
use 
Invitrogen 502327 
Broad spectrum  Ready to 
use 
Invitrogen 959743 
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